Medtronic PLC (MDT)

Medtronic Shares Slip Despite Earnings Beat as Fiscal 2027 Outlook Disappoints (MDT)June 3, 2026 9:57 AM
IH Market News Medtronic plc (NYSE:MDT) traded modestly lower in premarket activity on Wednesday after issuing fiscal 2027 earnings guidance that fell short of analyst expectations, overshadowing quarterly results that exceeded Wall Street forecasts. While the medical technology company delivered stronger-than-expected revenue and earnings for its fiscal fourth quarter, investors focused on a more cautious profit outlook for the year ahead. Fourth-Quarter Results Come in Ahead of Expectations For the quarter, Medtronic reported adjusted earnings of $1.55 per share, narrowly surpassing the consensus estimate of $1.54. Revenue reached $9.8 billion, exceeding analyst expectations of $9.63 billion and representing a 9.9% increase from the $8.9 billion generated during the same period a year earlier. On an organic basis, quarterly revenue grew 6.6%, reflecting continued momentum across several of the company’s key businesses. Fiscal 2027 Earnings Forecast Falls Below Consensus Despite the solid quarterly performance, Medtronic’s guidance for fiscal 2027 failed to meet market expectations. The company forecast adjusted earnings per share of $5.90 to $6.00 for the year, implying a midpoint of $5.95. That compares with analyst estimates of approximately $6.06 per share. Management also projected organic revenue growth of 6.75% to 7.25% for fiscal 2027. The softer earnings outlook weighed on investor sentiment, pushing shares lower in premarket trading. Management Highlights Strongest Revenue Growth in a Decade Chief Executive Officer Geoff Martha pointed to the company’s broad-based operational performance and sustained execution across its portfolio. “Our performance reflects the strongest annual top-line growth Medtronic has delivered in 10 years, powered by disciplined execution across our portfolio and continued operational rigor,” said Geoff Martha, Medtronic chairman and chief executive officer. Cardiovascular Segment Drives Growth The Cardiovascular Portfolio delivered the strongest performance among Medtronic’s business units during the quarter. Revenue from the segment reached $3.8 billion, increasing 13.8% on a reported basis and 10.1% organically. Growth was fueled by high-teen expansion in Cardiac Rhythm & Heart Failure products, while Cardiac Ablation Solutions posted particularly strong results. Global Cardiac Ablation Solutions revenue surged 78%, including a 124% increase in the United States, allowing the company to gain an additional eight percentage points of market share domestically. Other Business Units Post Steady Gains The Medical Surgical Portfolio generated revenue of $2.4 billion, representing organic growth of 5.1%. Meanwhile, the Neuroscience business recorded revenue of $2.8 billion and delivered organic growth of 3.0%. The results demonstrated continued demand across Medtronic’s diversified healthcare technology portfolio. Full-Year Revenue Climbs as Cash Generation Remains Strong For fiscal 2026, Medtronic generated total revenue of $36.4 billion, an increase of 8.4% on a reported basis and 5.8% organically. Adjusted earnings per share for the year reached $5.53, up 0.7% from the prior year. The company also generated $7.3 billion in operating cash flow and $5.4 billion in free cash flow, underscoring the strength of its financial position. During the year, Medtronic returned $4.2 billion to shareholders through dividends and other capital return initiatives. Dividend Increase Extends Long-Term Track Record Alongside its earnings report, Medtronic announced an increase in its quarterly dividend. The company raised the first-quarter fiscal 2027 dividend to $0.72 per share, marking its 49th consecutive year of dividend growth. The latest increase reinforces Medtronic’s long-standing commitment to returning capital to shareholders while continuing to invest in innovation and business expansion. Medtronic stock price Original: Medtronic Shares Slip Despite Earnings Beat as Fiscal 2027 Outlook Disappoints (MDT)

Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United StatesJune 3, 2026 7:05 AM
PR Newswire (US) Company also announces 510(k) pending for LigaSure™ RAS Maryland instrument on the Hugo RAS system, and 510(k) clearance for ProGrip™ Advanced self-gripping polypropylene mesh for use in robotic-assisted ventral hernia repair surgeriesGALWAY, Ireland, June 3, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced significant milestones to unlock expanded indications for the Hugo™ robotic-assisted surgery (RAS) system in the United States and to shape the future of surgery.General surgery indication including hernia repair — 510(k) clearance submittedEmbrace Gynecology Investigational Device Exemption (IDE) clinical study — completed enrollmentGynecologic surgery indication — 510(k) clearance submittedLigaSure™ RAS Maryland instrument — 510(k) clearance submittedProGrip™ Advanced mesh for use in robotic-assisted ventral hernia repair — 510(k) clearance receivedThese milestones build momentum for Medtronic's Surgical business and its purposeful launch of the Hugo RAS system, which received FDA clearance for urologic surgical procedures in December 2025 and is in commercial use at leading U.S. medical centers. With nearly five years of commercial experience across more than 35 countries in five continents, the Hugo RAS system has been used in tens of thousands of procedures and its safety and effectiveness is supported by hundreds of independently published scientific papers.Medtronic is the first and only company that can meet surgeons' needs across all surgical modalities — open, laparoscopic, and robotic-assisted — giving surgeons and health systems the choice and partnership required to build and grow successful surgery programs across care settings."These milestones and innovative technologies will unlock our ability to enhance the value of our partnership in general and gynecologic surgical procedures," said Matt Anderson, senior vice president and president of the Surgical business at Medtronic. "This isn't just a portfolio expansion, it's part of our ongoing commitment to unite instruments, intelligence, and human hands into one unique surgical ecosystem. One that enables every patient, everywhere, access to the best possible surgery."Expanding Hugo™ RAS indications and capabilities
The 510(k) filings for Hugo RAS system use in general surgery and gynecological procedures would significantly broaden the platform's clinical applicability in the U.S. and address growing demand for robotic-assisted minimally invasive options in these high-volume specialties. Medtronic has decades of experience collaborating with surgical teams in general surgery and gynecologic surgery to advance patient care globally; they are also indications where the Hugo RAS system is in clinical use in major markets outside the U.S. Bringing together technology surgeons trust and furthering its commitment to continually enhancing Hugo™ RAS system capabilities, today Medtronic announced it has submitted a 510(k) filing to the FDA for the LigaSure RAS Maryland instrument.Designed exclusively for use with the Valleylab™ FT10 energy platform on the Hugo™ RAS system, LigaSure RAS incorporates vessel-sealing technology that has been used in more than 35 million procedures across 65+ countries. LigaSure RAS was introduced on the Hugo RAS system in Europe in 2025."LigaSure technology has been transformative for surgery and integrating it onto the Hugo RAS system gives surgeons greater confidence and control during critical moments in complex procedures," said Dr. Matthew Kroh, chief medical officer within the Surgical business at Medtronic and a practicing general surgeon. "As more and more surgeons and patients demand robotic-assisted surgery, we need more access to technology and training, and Medtronic brings that choice in a very powerful way."Our most advanced robotic mesh1-3,†
Today Medtronic also announced it received FDA clearance for ProGrip™ Advanced, an evolution of existing mesh technologies to better align with the specific demands of robotic-assisted ventral hernia repair.ProGrip meshes have been used in more than 6 million procedures. ProGrip Advanced supports surgical efficiency in robotic procedures by making it easier to introduce through trocars, handle, deploy, and unfold compared to previously available products and comes in a variety of sizes to meet each patient's needs.2-3,‡Every year, nearly 470,000 ventral hernia repair procedures are performed in the U.S. — more and more are being done with the assistance of a robot, and an increasing number are performed at alternative sites of care as hospitals shift lower acuity procedures to ambulatory centers to support a patient-centered approach to care while managing cost pressures and capacity challenges. The Medtronic surgical ecosystem across open, laparoscopic, and robotic-assisted surgery is uniquely positioned to help solve these problems.Enrollment complete in Embrace Gynecology IDE study for the Hugo™ RAS system
Medtronic also announced today that the company has completed enrollment in the Embrace Gynecology Investigational Device Exemption (IDE) clinical study for the Hugo™ RAS system in the U.S. Embrace Gynecology is a prospective multicenter study to evaluate the safety and effectiveness of the Hugo™ RAS system when used in robotic-assisted gynecologic procedures. The study enrolled 70 patients across 5 U.S. hospitals.For more information, visit medtronic.com/hugoishere.†Compared to all Medtronic meshes indicated for robotic ventral hernia repair.‡Bench testing may not be indicative of clinical performance.Based on internal report 43463CR757, Memorandum — ProGrip™ advanced self-gripping polypropylene mesh — advanced robotic mesh.Based on internal report 43463CR506, Design verification report. Based on internal report 43463CR740, Design validation lab of ProGrip™ advanced self-gripping polypropylene mesh by MIS and open surgical approach.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Contacts:
Gary Jeanfaivre
Public Relations
+1-203-556-0777Ingrid Goldberg
Investor Relations
+1-763-505-2696 View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-submits-510k-filings-to-expand-hugo-robotic-assisted-surgery-system-into-general-and-gynecologic-specialties-in-the-united-states-302789147.htmlSOURCE Medtronic plc Original: Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States

Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 yearsJune 3, 2026 6:45 AM
PR Newswire (Canada) Disciplined execution and portfolio strength position Medtronic for continued momentum into fiscal year 2027GALWAY, Ireland, June 3, 2026 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2026 (FY26), which ended April 24, 2026.Q4 Key HighlightsRevenue of $9.8 billion, increased 9.9% as reported and 6.6% organic, 90 basis points ahead of Q4 implied guidanceGAAP diluted EPS of $0.96; non-GAAP diluted EPS of $1.55, ahead of guidanceCardiac Ablation Solutions revenue increased 78% globally, including 124% U.S. growth, gaining an additional 8 points of U.S. shareCardiovascular grew 10.1%, led by mid-single-digit growth in Cardiac Rhythm Management driven by continued strength across Cardiac Pacing Therapies and Defibrillation Solutions, including mid-teens growth in Micra™ and a strong OmniaSecure™ U.S. launchMedical Surgical reported strong performance, up 5.1%, led by Acute Care & Monitoring and Endoscopy, which were up low-double-digits and high-single-digits, respectivelyFiled submission to U.S. FDA for Hugo™ RAS for the general surgery and gynecologic indications, as well as LigaSure™ RAS vessel sealer; received FDA clearance for ProGrip™ AdvancedSecured FDA Clearance for Spine, Cranial and ENT indications and CE Mark for Spine and Cranial indications for Stealth AXiS™ Surgical SystemExecuted several tuck-in M&A and venture capital transactions to strengthen portfolios, accelerate growth, and expand into high-growth adjacencies: completed CathWorks acquisition in Coronary and Renal Denervation; announced intention to acquire both Scientia Vascular in Neurovascular and SPR Therapeutics in Neuromodulation (in May); entered into agreements with Merit Medical Systems to offer ViaVerte™ system in Neuromodulation; and an investment in Pulnovo Medical in CardiovascularDividend for Q1 FY27 increased to $0.72 per share, implying annual $2.88 per share; 49th consecutive year of dividend increasesFY26 Key Highlights FY26 revenue of $36.4 billion, adjusted revenue of $36.3 billion, increased 8.4% as reported and 5.8% organicFY26 GAAP diluted EPS of $3.73 increased 3.3%; non-GAAP diluted EPS of $5.53 increased 0.7%FY26 operating margin was flat year-over-year; FY26 non-GAAP operating margin decreased 130 basis points, or 150 basis points constant currencyFY26 operating profit of $6.467 billion increased 8.6%; FY26 non-GAAP operating profit of $8.856 billion increased 2.4%, and decreased 0.6% constant currencyFY26 cash from operations of $7.3 billion with free cash flow of $5.4 billion; closed FY26 with $9.2 billion cash and investmentsCompany returned $4.2 billion to shareholders in FY26"Our performance reflects the strongest annual top-line growth Medtronic has delivered in 10 years, powered by disciplined execution across our portfolio and continued operational rigor," said Geoff Martha, Medtronic chairman and chief executive officer. "These results represent the compounding impact of deliberate choices we've made to strengthen our strategy, sharpen execution, and invest in the areas that will drive our future. We saw continued strength in some of our largest businesses like CRM, CST and Surgical, and we are building momentum in our highest growth opportunities, such as Affera, Symplicity, Hugo, Altaviva and Stealth AXiS. Together with the investments we're making in our pipeline, Medtronic is well positioned to deliver sustained growth and long-term value."Q4 Financial Results
Medtronic reported Q4 worldwide revenue of $9.807 billion, an increase of 9.9% as reported and 6.6% on an organic basis. The Q4 FY26 organic revenue growth comparison excludes:Other revenue of $34 million in the current year versus $31 million in the prior yearRevenue from the Dutch Obesity Clinic (NOK) divestiture with no revenue in the current year and $17 million in the prior yearForeign exchange benefit of $308 million on the remaining net salesQ4 revenue included:Cardiovascular Portfolio revenue of $3.797 billion increased 13.8% as reported and 10.1% organic, with high-teens increase in Cardiac Rhythm & Heart Failure, low-single digit increase in Structural Heart & Aortic, and low-single digit increase in Coronary & Peripheral Vascular, all on an organic basisNeuroscience Portfolio revenue of $2.751 billion increased 5.0% reported and 3.0% organic, with low-single digit increase in Neuromodulation, Cranial & Spinal Technologies, and Specialty Therapies, all on an organic basisMedical Surgical Portfolio revenue of $2.388 billion increased 8.0% as reported and 5.1% organic, with low-single digit increase in Surgical & Endoscopy, and low-double-digit increase in Acute Care & Monitoring, all on an organic basisDiabetes business revenue of $837 million increased 15.0% as reported and 8.1% organic1Q4 GAAP operating profit and operating margin were $1.873 billion and 19.1%, respectively, an increase of 30.4% and 300 bps, respectively. As detailed in the financial schedules included at the end of the release, Q4 non-GAAP operating profit and operating margin were $2.500 billion and 25.5%, respectively, an increase of 0.6% and a decrease of 230 basis points, respectively. The operating margin includes impacts of 160 basis points from the MiniMed Blackstone payment and 80 basis points from tariffs.Q4 GAAP net income and diluted earnings per share (EPS) were $1.243 billion and $0.96, respectively, representing increases of 17.6% and 17.1%, respectively. As detailed in the financial schedules included at the end of this release, Q4 non-GAAP net income and non-GAAP diluted EPS were $1.998 billion and $1.55, respectively, representing decreases of 3.9% and 4.3%, respectively.FY26 Financial Results Medtronic reported FY26 worldwide revenue of $36.364 billion and adjusted revenue of $36.325 billion, an increase of 8.4% as reported and 5.8% on an organic basis. The FY26 organic revenue growth comparison excludes:Other revenue of $174 million in the current year and $48 million in the prior yearRevenue from the Dutch Obesity Clinic (NOK) divestiture of $5 million in the current year and $48 million in the prior year; andForeign exchange benefit of $819 million on the remaining net salesFY26 GAAP operating profit and operating margin were $6.467 billion and 17.8%, respectively, an increase of 8.6% and flat year-over-year, respectively. As detailed in the financial schedules included at the end of the release, FY26 non-GAAP operating profit and operating margin were $8.856 billion and 24.4%, respectively, an increase of 2.4% and a decrease of 130 basis points, respectively. On a constant currency basis, FY26 non-GAAP operating profit and operating margin decreased 0.6% and 150 basis points, respectively. The operating margin includes impacts of 45 basis points from the MiniMed Blackstone payment and 50 basis points from tariffs.FY26 GAAP net income and diluted EPS were $4.801 billion and $3.73, respectively, representing increases of 3.0% and 3.3%, respectively. As detailed in the financial schedules included at the end of this release, FY26 non-GAAP net income and non-GAAP diluted EPS were $7.120 billion and $5.53, respectively, representing increases of 0.6% and 0.7%, respectively. Included in FY26 non-GAAP diluted EPS was a $0.15 impact from foreign currency. FY26 non-GAAP diluted EPS on a constant currency basis decreased 2.0%.FY26 cash from operations of $7.330 billion increased 4.1%. FY26 free cash flow of $5.426 billion increased 4.6%, representing free cash flow conversion from non-GAAP net earnings of 76%.Dividend Increase
The company today announced that effective June 3, 2026, the Medtronic board of directors approved an increase in Medtronic's cash dividend for the first quarter of fiscal year 2027, raising the quarterly amount to $0.72 per ordinary share. This would translate into an annual amount of $2.88 per ordinary share. Today's announcement marks the 49th consecutive year of an increase in the dividend payment. The dividend is payable on July 17, 2026, to shareholders of record at the close of business on June 26, 2026.Guidance
The company is guiding to FY27 organic revenue growth of 6.75% to 7.25%. FY27 organic revenue growth guidance includes the impact of the 53rd week as well as revenue from the Diabetes business for the full fiscal year. Consistent with prior quarters, the organic revenue growth guidance excludes the impact of foreign currency exchange and Other revenue.The company is guiding to FY27 diluted non-GAAP EPS in the range of $5.90 to $6.00, representing FY27 diluted non-GAAP EPS growth in the range of 6.7% to 8.5%. This guidance includes the benefit of the 53rd week, increased M&A, as well as impacts from tariffs, interest, tax expense, and assumes consolidation of the Diabetes business for the full 12 months of FY27. This guidance also includes an estimated neutral to 1% accretive impact from foreign currency exchange based on recent rates."We are pleased to have delivered results ahead of expectations on both revenue and EPS," said Thierry Piéton, Medtronic chief financial officer. "As we look to FY27, we are entering the year with strong momentum, a resilient operating foundation, and a clear path to deliver durable growth. With a uniquely robust pipeline, our tuck-in M&A and investment strategy activated, and continued financial discipline, we are poised to build on our FY26 performance."Video Webcast Information
Medtronic will host a video webcast today, June 3, at 7:45 a.m. EST (6:45 a.m. CST) to provide information about its business for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Quarterly Earnings icon at investorrelations.medtronic.com, and this earnings release will be archived at news.medtronic.com. Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Past Events and Presentations link under the News & Events drop-down at investorrelations.medtronic.com.Financial Schedules and Earnings Presentation
The fourth quarter and full year financial schedules and non-GAAP reconciliations can be viewed by clicking on the Quarterly Earnings link at investorrelations.medtronic.com. To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here. To view the earnings presentation, click here.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow on LinkedIn.FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, material acquisition and divestiture transactions, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.NON-GAAP FINANCIAL MEASURES
This press release contains guidance and financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. Certain information in this press release also includes calculations or figures that have been prepared internally and have not been reviewed or audited by our independent registered public accounting firm. Use of different methods for preparing, calculating or presenting information may lead to differences and such differences may be material.Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, revenue in the current and prior year reported as "Other", as well as significant acquisitions, divestitures, or other significant discrete items. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.FINANCIAL COMPARISONS
References to quarterly or annual figures increasing, decreasing, or remaining flat are in comparison to fiscal year 2025, and references to sequential changes are in comparison to the prior fiscal quarter. Unless stated otherwise, quarterly and annual rates and ranges are given on an organic basis. References to organic revenue growth exclude the impact of foreign currency, fourth quarter and full year revenue in the current and prior year reported as "Other", as well as significant acquisitions, divestitures, or other significant discrete items. Unless stated otherwise, all references to share gains or losses are as of the most recently completed calendar quarter, on a revenue basis, and in comparison, to the same period in the prior year.TRANSACTION DETAILS
The separation of our Diabetes business is expected to occur through a series of capital markets transactions, which may include a spin-off, split-off, offering, or combination thereof. While an offering and split-off is the company's current preferred separation structure, a final decision has not been reached at this time.Contacts:
Justin Paquette
Public Relations
+1-612-271-7935Ingrid Goldberg
Investor Relations
+1-763-505-2696____________________________________1The Diabetes results presented here may not correspond to the same financial statement information presented by MiniMed Group, Inc. (MiniMed) due to MiniMed's financials being prepared on a carve out basis through the date of the company's initial public offering (IPO) and on a standalone basis post IPO.  MEDTRONIC PLCWORLD WIDE REVENUE(1)(Unaudited)

FOURTH QUARTER

FISCAL YEAR
REPORTED


ORGANIC

REPORTED


ORGANIC(in millions)FY26
FY25
Growth
Currency
Impact(5)
FY26(6)
FY25(6)
Growth

FY26
FY25
Growth
Currency
Impact(5)
FY26(7)
FY25(7)
GrowthCardiovascular$    3,797
$    3,336
13.8 %
$       124
$    3,673
$    3,336
10.1 %

$   13,976
$   12,481
12.0 %
$       337
$   13,639
$   12,481
9.3 %Cardiac Rhythm & Heart Failure2,110
1,733
21.8
62
2,048
1,733
18.2

7,504
6,392
17.4
169
7,335
6,392
14.8Structural Heart & Aortic1,002
944
6.2
40
963
944
2.0

3,817
3,554
7.4
111
3,706
3,554
4.3Coronary & Peripheral Vascular685
659
4.0
22
663
659
0.6

2,656
2,535
4.8
57
2,598
2,535
2.5Neuroscience2,751
2,620
5.0
52
2,699
2,620
3.0

10,287
9,846
4.5
133
10,154
9,846
3.1Cranial & Spinal Technologies1,403
1,342
4.6
18
1,385
1,342
3.3

5,222
4,973
5.0
49
5,173
4,973
4.0Specialty Therapies806
759
6.2
21
785
759
3.4

2,997
2,940
1.9
49
2,948
2,940
0.3Neuromodulation542
520
4.3
13
528
520
1.7

2,068
1,932
7.0
36
2,033
1,932
5.2Medical Surgical2,388
2,212
8.0
81
2,306
2,195
5.1

8,815
8,407
4.9
210
8,601
8,359
2.9Surgical & Endoscopy1,820
1,709
6.5
69
1,750
1,692
3.5

6,764
6,498
4.1
176
6,585
6,450
2.1Acute Care & Monitoring568
503
12.9
12
556
503
10.5

2,051
1,909
7.4
34
2,017
1,909
5.6Total Reportable Segments8,936
8,168
9.4
258
8,678
8,151
6.5

33,079
30,734
7.6
680
32,394
30,686
5.6Diabetes(2)837
728
15.0
50
787
728
8.1

3,112
2,755
12.9
140
2,972
2,755
7.9Other(3)34
31
10.0
—
—
—
—

174
48
NM(4)
4
—
—
—TOTAL$    9,807
$    8,927
9.9 %
$       308
$    9,466
$    8,879
6.6 %

$   36,364
$   33,537
8.4 %
$       824
$   35,366
$   33,441
5.8 %

(1)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.(2)The Diabetes results presented here may not correspond to the same financial statement information presented by MiniMed Group, Inc. (MiniMed). The Diabetes Business as reported by Medtronic is prepared on a different basis than standalone Medtronic due to MiniMed's financials being prepared on a carve out basis through the date of the company's initial public offering (IPO) and on a standalone basis post IPO.(3)Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, and for the year-to-date figures, adjustments to the Company's Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015.(4)Not meaningful (NM)(5)The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.(6)The three months ended April 24, 2026 excludes $342 million of revenue adjustments related to $34 million of inorganic revenue for the transition activity noted in (2) and $308 million of favorable currency impact on the remaining net sales. The three months ended April 25, 2025 excludes $48 million of revenue adjustments related to $31 million of inorganic revenue for the transition activity noted in (2) and $17 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.(7)The twelve months ended April 24, 2026 excludes $998 million of revenue adjustments, including $39 million reduction in the Italian payback accruals due to changes in estimates further described in note (2), $135 million of inorganic revenue for the transition activity noted in (2), $5 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division, and $819 million of favorable currency impact on the remaining net sales. The twelve months ended April 25, 2025 excludes $96 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $137 million of inorganic revenue for the transition activity noted in (2), and $48 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.MEDTRONIC PLCU.S. REVENUE(1)(2)(Unaudited)

FOURTH QUARTER

FISCAL YEAR
REPORTED
ORGANIC

REPORTED
ORGANIC(in millions)FY26
FY25
Growth
FY26
FY25
Growth

FY26
FY25
Growth
FY26
FY25
GrowthCardiovascular$    1,775
$    1,563
13.6 %
$    1,775
$    1,563
13.6 %

$     6,435
$     5,804
10.9 %
$     6,435
$     5,804
10.9 %Cardiac Rhythm & Heart Failure1,105
875
26.3
1,105
875
26.3

3,812
3,184
19.7
3,812
3,184
19.7Structural Heart & Aortic387
404
(4.0)
387
404
(4.0)

1,515
1,532
(1.1)
1,515
1,532
(1.1)Coronary & Peripheral Vascular282
284
(0.6)
282
284
(0.6)

1,107
1,088
1.7
1,107
1,088
1.7Neuroscience1,812
1,782
1.7
1,812
1,782
1.7

6,875
6,713
2.4
6,875
6,713
2.4Cranial & Spinal Technologies1,031
999
3.2
1,031
999
3.2

3,864
3,723
3.8
3,864
3,723
3.8Specialty Therapies431
431
—
431
431
—

1,635
1,666
(1.9)
1,635
1,666
(1.9)Neuromodulation350
352
(0.6)
350
352
(0.6)

1,376
1,324
3.9
1,376
1,324
3.9Medical Surgical1,021
946
8.0
1,021
946
8.0

3,778
3,664
3.1
3,778
3,664
3.1Surgical & Endoscopy694
668
3.9
694
668
3.9

2,614
2,595
0.7
2,614
2,595
0.7Acute Care & Monitoring328
278
17.9
328
278
17.9

1,164
1,068
9.0
1,164
1,068
9.0Total Reportable Segments4,609
4,291
7.4
4,609
4,291
7.4

17,088
16,181
5.6
17,088
16,181
5.6Diabetes(3)239
240
(0.2)
239
240
(0.2)

934
923
1.2
934
923
1.2Other(4)21
17
27.6
—
—
—

81
68
19.4
—
—
—TOTAL$    4,869
$    4,547
7.1 %
$    4,848
$    4,530
7.0 %

$   18,103
$   17,171
5.4 %
$   18,022
$   17,104
5.4 %

(1)U.S. includes the United States and U.S. territories.(2)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.(3)The Diabetes results presented here may not correspond to the same financial statement information presented by MiniMed Group, Inc. (MiniMed). The Diabetes Business as reported by Medtronic is prepared on a different basis than standalone Medtronic due to MiniMed's financials being prepared on a carve out basis through the date of the company's initial public offering (IPO) and on a standalone basis post IPO.(4)Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested.MEDTRONIC PLCINTERNATIONAL REVENUE(1)(Unaudited)

FOURTH QUARTER

FISCAL YEAR
REPORTED


ORGANIC

REPORTED


ORGANIC(in millions)FY26
FY25
Growth
Currency
Impact(5)
FY26(6)
FY25(6)
Growth

FY26
FY25
Growth
Currency
Impact(5)
FY26(7)
FY25(7)
GrowthCardiovascular$     2,023
$     1,773
14.1 %
$        124
$     1,898
$     1,773
7.1 %

$     7,541
$     6,677
12.9 %
$        337
$     7,204
$     6,677
7.9 %Cardiac Rhythm & Heart Failure1,005
858
17.1
62
943
858
9.9

3,691
3,208
15.1
169
3,522
3,208
9.8Structural Heart & Aortic615
541
13.8
40
575
541
6.4

2,301
2,022
13.8
111
2,190
2,022
8.3Coronary & Peripheral Vascular403
375
7.5
22
380
375
1.6

1,549
1,447
7.0
57
1,491
1,447
3.1Neuroscience938
838
12.0
52
886
838
5.8

3,412
3,133
8.9
133
3,279
3,133
4.7Cranial & Spinal Technologies372
343
8.6
18
354
343
3.3

1,358
1,250
8.6
49
1,309
1,250
4.7Specialty Therapies374
328
14.3
21
354
328
8.0

1,362
1,274
6.9
49
1,313
1,274
3.1Neuromodulation191
167
14.5
13
178
167
6.5

692
608
13.8
36
656
608
7.9Medical Surgical1,366
1,266
7.9
81
1,285
1,249
2.9

5,037
4,744
6.2
210
4,823
4,695
2.7Surgical & Endoscopy1,126
1,041
8.2
69
1,057
1,024
3.2

4,151
3,903
6.3
176
3,971
3,855
3.0Acute Care & Monitoring240
225
6.8
12
228
225
1.4

887
841
5.5
34
853
841
1.4Total Reportable Segments4,327
3,877
11.6
258
4,069
3,860
5.4

15,991
14,553
9.9
680
15,306
14,505
5.5Diabetes(2)598
489
22.4
50
548
489
12.2

2,178
1,832
18.9
140
2,038
1,832
11.2Other(3)13
14
(10.4)
—
—
—
—

93
(20)
NM(4)
4
—
—
—TOTAL$     4,938
$     4,380
12.8 %
$        308
$     4,618
$     4,348
6.2 %

$   18,261
$   16,365
11.6 %
$        824
$   17,344
$   16,337
6.2 %

(1)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.(2)The Diabetes results presented here may not correspond to the same financial statement information presented by MiniMed Group, Inc. (MiniMed). The Diabetes Business as reported by Medtronic is prepared on a different basis than standalone Medtronic due to MiniMed's financials being prepared on a carve out basis through the date of the company's initial public offering (IPO) and on a standalone basis post IPO.(3)Includes the historical operations and ongoing transition agreements from businesses the Company has exited and divested and for the year-to-date figures, adjustments to the Company's Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015.(4)Not meaningful (NM)(5)The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.(6)The three months ended April 24, 2026 excludes $321 million of revenue adjustments, including $13 million of inorganic revenue for the transition activity noted in (2) and $308 million of favorable currency impact on the remaining net sales. The three months ended April 25, 2025 excludes $31 million of revenue adjustments related to $14 million of inorganic revenue for the transition activity noted in (2) and $17 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.(7)The twelve months ended April 24, 2026 excludes $917 million of revenue adjustments, including $39 million reduction in the Italian payback accruals due to changes in estimates further described in note (2), $54 million of inorganic revenue for the transition activity noted in (2), $5 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division, and $819 million of favorable currency impact on the remaining net sales. The twelve months ended April 25, 2025 excludes $28 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $70 million of inorganic revenue for the transition activity noted in (2), and $48 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.MEDTRONIC PLCCONSOLIDATED STATEMENTS OF INCOME(Unaudited) 

Three months ended
Fiscal year ended(in millions, except per share data)April 24, 2026
April 25, 2025
April 24, 2026
April 25, 2025Net sales$               9,807
$               8,927
$             36,364
$             33,537Costs and expenses:






Cost of products sold, excluding amortization of intangible assets3,398
3,147
12,721
11,632Research and development expense671
684
2,873
2,732Selling, general, and administrative expense3,056
2,721
11,784
10,849Amortization of intangible assets409
564
1,772
1,807Restructuring charges, net118
147
249
267Certain litigation charges, net23
214
113
317Other operating expense (income), net260
15
386
(23)Operating profit1,873
1,436
6,467
5,955Other non-operating expense (income), net(138)
1
(384)
(402)Interest expense, net176
174
715
729Income before income taxes1,834
1,261
6,136
5,628Income tax provision575
199
1,299
936Net income1,259
1,061
4,837
4,691Net income attributable to noncontrolling interests(16)
(5)
(37)
(29)Net income attributable to Medtronic$               1,243
$               1,057
$               4,801
$               4,662Basic earnings per share$                 0.97
$                 0.82
$                 3.75
$                 3.63Diluted earnings per share$                 0.96
$                 0.82
$                 3.73
$                 3.61Basic weighted average shares outstanding1,281.5
1,282.3
1,281.8
1,285.6Diluted weighted average shares outstanding1,288.2
1,287.7
1,288.1
1,289.9
The data in the schedule above has been intentionally rounded to the nearest million, and therefore, the quarterly amounts may not sum to the fiscal year-to-date amounts.MEDTRONIC PLCGAAP TO NON-GAAP RECONCILIATIONS(1)(Unaudited) 

Three months ended April 24, 2026(in millions, except per share data)Net
Sales
Cost of
Products
Sold
Gross
Margin
Percent
Operating
Profit
Operating
Profit
Percent
Income
Before
Income
Taxes
Net Income
attributable
to
Medtronic
Diluted
EPS
Effective
Tax RateGAAP$  9,807
$   3,398
65.4 %
$     1,873
19.1 %
$    1,834
$       1,243
$     0.96
31.3 %Non-GAAP adjustments:
















Amortization of intangible assets—
—
—
409
4.2
409
334
0.26
18.3Restructuring and associated costs(2)—
—
—
118
1.2
118
88
0.07
26.0Acquisition and divestiture-related items(3)—
(5)
0.1
77
0.8
77
64
0.05
17.7Certain litigation charges, net—
—
—
23
0.2
23
17
0.01
27.3(Gain)/loss on minority investments(4)—
—
—
—
—
(15)
(7)
(0.01)
50.0Certain tax adjustments, net(5)—
—
—
—
—
—
259
0.20
—Non-GAAP$  9,807
$   3,392
65.4 %
$     2,500
25.5 %
$    2,447
$       1,998
$     1.55
17.7 %Currency impact(308)
(28)
(0.8)
(91)
(0.1)




(0.05)

Currency Adjusted$  9,499
$   3,364
64.6 %
$     2,409
25.4 %




$     1.50




















Three months ended April 25, 2025(in millions, except per share data)Net
Sales
Cost of
Products
Sold
Gross
Margin
Percent
Operating
Profit
Operating
Profit
Percent
Income
Before
Income
Taxes
Net Income
attributable
to
Medtronic
Diluted
EPS
Effective
Tax RateGAAP$  8,927
$   3,147
64.7 %
$     1,436
16.1 %
$    1,261
$       1,057
$     0.82
15.8 %Non-GAAP adjustments:
















Amortization of intangible assets(6)—
—
—
564
6.3
564
455
0.35
19.3Restructuring and associated costs(2)—
(2)
—
149
1.7
149
114
0.09
23.5Acquisition and divestiture-related items(3)—
(21)
0.2
109
1.2
109
97
0.08
11.0Certain litigation charges, net—
—
—
214
2.4
214
163
0.13
23.4(Gain)/loss on minority investments(4)—
—
—
—
—
172
170
0.13
0.6Medical device regulations(7)—
(10)
0.1
14
0.2
14
12
0.01
21.4Certain tax adjustments, net—
—
—
—
—
—
13
0.01
—Non-GAAP$  8,927
$   3,113
65.1 %
$     2,486
27.8 %
$    2,483
$       2,080
$     1.62
16.0 %
See description of non-GAAP financial measures contained in the press release dated June 3, 2026.
(1)The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.(2)The charges primarily relate to employee termination benefits, facility related and contract termination costs, and asset write offs.(3)The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. Exit of business-related charges primarily relate to the impending separation of the Diabetes Business, and for the three months ended April 24, 2026, costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System.(4)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.(5)The net charges primarily relates to the impact of an intercompany sale of intellectual property, the net tax charge as a result of the separation of the Diabetes Business, and amortization of previously established deferred tax assets arising from intercompany intellectual property transactions.(6)The Company recognized $151 million of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio.(7)The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs.MEDTRONIC PLCGAAP TO NON-GAAP RECONCILIATIONS(1)(Unaudited) 

Fiscal year ended April 24, 2026(in millions, except per share data)Net
Sales
Cost of
Products
Sold
Gross
Margin
Percent
Operating
Profit
Operating
Profit
Percent
Income
Before
Income
Taxes
Net Income
attributable
to Medtronic
Diluted
EPS
Effective
Tax RateGAAP$  36,364
$  12,721
65.0 %
$     6,467
17.8 %
$    6,136
$         4,801
$     3.73
21.2 %Non-GAAP adjustments:
















Amortization of intangible assets(2)—
—
—
1,772
4.9
1,772
1,444
1.12
18.6Restructuring and associated costs(3)—
(106)
0.3
370
1.0
370
290
0.23
21.6Acquisition and divestiture-related items(4)—
(27)
—
173
0.5
173
137
0.11
21.4Certain litigation charges, net—
—
—
113
0.3
113
89
0.07
20.4(Gain)/loss on minority investments(5)—
—
—
—
—
131
130
0.10
—Other(6)(39)
—
—
(39)
(0.1)
(39)
(30)
(0.02)
20.5Certain tax adjustments, net(7)—
—
—
—
—
—
260
0.20
—Non-GAAP$  36,325
$  12,589
65.3 %
$     8,856
24.4 %
$    8,656
$         7,120
$     5.53
17.3 %Currency impact(821)
(76)
(0.6)
(262)
(0.2)




(0.15)

Currency Adjusted$  35,504
$  12,512
64.8 %
$     8,594
24.2 %




$     5.38




















Fiscal year ended April 25, 2025(in millions, except per share data)Net
Sales
Cost of
Products
Sold
Gross
Margin
Percent
Operating
Profit
Operating
Profit
Percent
Income
Before
Income
Taxes
Net Income
attributable
to Medtronic
Diluted
EPS
Effective
Tax RateGAAP$  33,537
$  11,632
65.3 %
$     5,955
17.8 %
$    5,628
$         4,662
$     3.61
16.6 %Non-GAAP adjustments:
















Amortization of intangible assets(2)—
—
—
1,807
5.3
1,807
1,471
1.14
18.5Restructuring and associated costs(3)—
(26)
0.1
303
0.9
303
238
0.18
21.5Acquisition and divestiture-related items(4)—
(38)
0.1
124
0.4
124
101
0.08
18.5Certain litigation charges, net—
—
—
317
0.9
317
249
0.19
21.5(Gain)/loss on minority investments(5)—
—
—
—
—
213
185
0.14
12.2Medical device regulations(8)—
(38)
0.1
52
0.2
52
42
0.03
19.2Other(6)90
—
0.2
90
0.3
90
70
0.05
22.2Certain tax adjustments, net(7)—
—
—
—
—
—
62
0.05
—Non-GAAP$  33,627
$  11,530
65.7 %
$     8,648
25.7 %
$    8,533
$         7,079
$     5.49
16.7 %
See description of non-GAAP financial measures contained in the press release dated June 3, 2026.
(1)The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.(2)The Company recognized $121 million and $151 million of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio for the fiscal year ended April 24, 2026 and April 25, 2025, respectively.(3)The charges primarily relate to employee termination benefits, facility related and contract termination costs, and asset write offs.(4)The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. Exit of business-related charges primarily relate to the impending separation of the Diabetes Business and costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System.(5)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.(6)Reflects adjustments to the Company's Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015.(7)The net charges for the fiscal year ended April 24, 2026 primarily relates to the impact of an intercompany sale of intellectual property, the net tax charge as a result of the separation of the Diabetes Business, and amortization of previously established deferred tax assets arising from intercompany intellectual property transactions, which were partially offset by a tax benefit recognized due to a change in estimate of accrued interest on uncertain tax positions. The charges for the fiscal year ended April 25, 2025 primarily includes amortization of previously established deferred tax assets from intercompany intellectual property transactions.(8)The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs.MEDTRONIC PLCGAAP TO NON-GAAP RECONCILIATIONS(1)(Unaudited) 

Three months ended April 24, 2026(in millions)Net Sales
SG&A
Expense
SG&A
Expense as
a % of Net
Sales
R&D
Expense
R&D
Expense
as a % of
Net Sales
Other
Operating
Expense
(Income),
net
Other
Operating
Exp./(Inc.),
net as a % of
Net Sales
Other Non-
Operating
Expense
(Income), netGAAP$      9,807
$     3,056
31.2 %
$       671
6.8 %
$         260
2.7 %
$          (138)Non-GAAP adjustments:














Acquisition and divestiture-related items(2)—
(67)
(0.7)
(1)
—
(3)
—
—(Gain)/loss on minority investments(3)—
—
—
—
—
—
—
15Non-GAAP$      9,807
$     2,989
30.5 %
$       670
6.8 %
$         257
2.6 %
$          (123)

Fiscal year ended April 24, 2026(in millions)Net Sales
SG&A
Expense
SG&A
Expense as
a % of Net
Sales
R&D
Expense
R&D
Expense
as a % of
Net Sales
Other
Operating
Expense
(Income),
net
Other
Operating
Exp./(Inc.),
net as a % of
Net Sales
Other Non-
Operating
Expense
(Income), netGAAP$    36,364
$   11,784
32.4 %
$    2,873
7.9 %
$         386
1.1 %
$          (384)Non-GAAP adjustments:














Restructuring and associated costs(4)—
(15)
—
—
—
—
—
—Acquisition and divestiture-related items(2)—
(164)
(0.5)
(1)
—
18
—
—Other(5)(39)
—
—
—
—
—
—
—(Gain)/loss on minority investments(3)—
—
—
—
—
—
—
(131)Non-GAAP$    36,325
$   11,605
31.9 %
$    2,872
7.9 %
$         404
1.1 %
$          (515)
See description of non-GAAP financial measures contained in the press release dated June 3, 2026.
(1)The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.(2)The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and for the fiscal year ended April 24, 2026, gains related to certain business or asset sales. Exit of business-related charges primarily relate to the impending separation of the Diabetes Business and costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System.(3)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.(4)The charges primarily relate to employee termination benefits, facility related and contract termination costs, and asset write offs.(5)Reflects adjustments to the Company's Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015.MEDTRONIC PLCGAAP TO NON-GAAP RECONCILIATIONS(1)(Unaudited)

Fiscal Year(in millions)2026
2025
2024Net cash provided by operating activities$                      7,330
$                      7,044
$                      6,787Additions to property, plant, and equipment(1,904)
(1,859)
(1,587)Free Cash Flow(2)$                      5,426
$                      5,185
$                      5,200
See description of non-GAAP financial measures contained in the press release dated June 3, 2026.
(1)The data in this schedule has been intentionally rounded to the nearest million, and therefore, may not sum.(2)Free cash flow represents operating cash flows less property, plant, and equipment additions.MEDTRONIC PLCCONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)

Fiscal Year(in millions)2026
2025
2024Operating Activities:




Net income$           4,837
$           4,691
$           3,705Adjustments to reconcile net income to net cash provided by operating activities:




  Depreciation and amortization2,958
2,861
2,647  Provision for credit losses136
123
90  Deferred income taxes51
(316)
(508)  Stock-based compensation457
429
393  Asset impairments and related inventory write-downs—
—
371  Other, net314
310
573  Change in operating assets and liabilities, net of acquisitions and divestitures:




Accounts receivable, net(200)
(433)
(391)Inventories(404)
(292)
(139)Accounts payable and accrued liabilities46
209
391Other operating assets and liabilities(865)
(538)
(345)Net cash provided by operating activities7,330
7,044
6,787Investing Activities:




Acquisitions, net of cash acquired(406)
(98)
(211)Additions to property, plant, and equipment(1,904)
(1,859)
(1,587)Purchases of investments(8,725)
(8,226)
(7,748)Sales and maturities of investments8,105
8,495
7,441Other investing activities, net(4)
(249)
(261)Net cash used in investing activities(2,934)
(1,937)
(2,366)Financing Activities:




Change in current debt obligations, net9
(1,070)
1,073Issuance of long-term debt1,747
3,209
—Payments on long-term debt(2,930)
—
—Dividends to shareholders(3,639)
(3,589)
(3,666)Issuance of ordinary shares516
508
284Repurchase of ordinary shares(1,035)
(3,235)
(2,138)Proceeds from MiniMed initial public offering538
—
—Other financing activities, net44
(184)
(3)Net cash used in financing activities(4,751)
(4,361)
(4,450)Effect of exchange rate changes on cash and cash equivalents85
188
(230)Net change in cash and cash equivalents(269)
934
(259)Cash and cash equivalents at beginning of period2,218
1,284
1,543Cash and cash equivalents at end of period$           1,949
$           2,218
$           1,284Supplemental Cash Flow Information




Cash paid for:




Income taxes$           1,942
$           1,819
$           1,622Interest774
762
826
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-reports-fourth-quarter-and-full-year-fiscal-2026-results-delivers-highest-annual-revenue-growth-in-10-years-302789415.htmlSOURCE Medtronic plc Original: Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years

Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadensJune 3, 2026 6:55 AM
PR Newswire (US) Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic's commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of technologiesGALWAY, Ireland, June 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced strategic investments in two privately held companies focused on the development of intracardiac echocardiography (ICE) catheter technologies. ICE catheters provide real-time, high-resolution imaging of the heart during electrophysiology (EP) procedures for cardiac arrhythmias such as atrial fibrillation (Afib). Medtronic intends to integrate ICE into the Affera™ mapping and ablation system to continue building on the differentiated value proposition of the Affera ecosystem.The investments further reinforce the momentum of the cardiac ablation business at Medtronic and include Beluga Medical, a premarket-stage company located in California developing a next-generation ICE product, and CardioACC, an early commercial-stage company based in Shenzhen, China. CardioACC received National Medical Products Administration approval for its ICE system in 2025."The incredible growth of our business demonstrates the demand for better technologies in electrophysiology, and we are leaning into opportunities that support our long-term portfolio roadmap," said Rebecca Seidel, president of the Cardiac Ablation Solutions business, which is part of the Cardiovascular Portfolio. "ICE catheters are an important component of ablation procedures today, and we intend for our Affera platform to evolve to include this capability. These investments represent another step to support expansion of our leadership position in EP as we work to bring new and innovative technologies to each market."The investments in cardiac ablation continue the recent cadence of strategic transactions at Medtronic to strengthen the company's leadership within its core franchises. Medtronic continues to prioritize high-growth opportunities to complement its core businesses and deliver sustained value for physicians and hospital partners."Intracardiac echocardiography has become a procedural essential in electrophysiology, giving physicians real-time visualization that can support more confident decision making throughout an ablation case," said Khaldoun Tarakji, M.D., MPH, vice president, chief medical officer, Cardiac Ablation Solutions business, which is part of the Cardiovascular Portfolio at Medtronic. "By investing in ICE technologies, we are strategically positioning ourselves to evolve and strengthen the Affera ecosystem over time, with the goal of continuing to advance integrated imaging and mapping workflows, improve procedural efficiency, and deliver better outcomes for patients."Both ICE catheter companies will continue to operate independently.About the Medtronic Cardiac Ablation Solutions Business 
Medtronic was the first company with two pulsed field ablation (PFA) offerings for physicians and patients. The PulseSelect™ Pulsed Field Ablation System offers physicians a safe, single-shot solution for pulmonary vein isolation (PVI) and is now available in more than 35 countries.Sphere-9™ is the only all-in-one, dual energy mapping and ablation catheter for treatment of persistent AFib and concomitant CTI-dependent atrial flutter. The Affera system, together with the Sphere-9 catheter, enables physician treatment flexibility with its wide area focal design and 9 mm lattice. Sphere-9 is approved in the U.S., Europe, Australia, New Zealand and Japan, with global expansion ongoing. The Sphere-360 catheter is approved in Europe and investigational in the United States. For more information on the Affera system, the Sphere-9 catheter and the Sphere-360 catheter, visit Medtronic.com.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Contacts:
Leslie Williamson
Public Relations
+1-612-227-5099Ingrid Goldberg
Investor Relations
 +1-763-505-2696  View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-strategic-investments-to-support-future-expansion-of-cardiac-ablation-portfolio-as-physician-demand-for-affera-technologies-broadens-302789277.htmlSOURCE Medtronic plc Original: Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens

Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic painMay 20, 2026 9:15 AM
PR Newswire (US) Acquisition will enhance Medtronic's Neuromodulation portfolio with temporary peripheral nerve stimulation (PNS) technology, enabling earlier intervention for chronic pain sufferersGALWAY, Ireland, May 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global healthcare technology leader, today announced its intent to acquire SPR Therapeutics, Inc. (SPR), a privately held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation (PNS) therapies for chronic pain management. The transaction consists of an upfront cash payment of approximately $650 million for all the outstanding equity in SPR. The acquisition continues Medtronic's momentum in driving strategic deals that further build out the company's core franchises.Drawing on Medtronic's 50 years of neuromodulation leadership, including the industry's broadest pain therapy portfolio1, this planned acquisition will increase Medtronic's ability to reach and support more people with complementary, minimally invasive pain relief options earlier in their care continuum.Chronic pain affects nearly 50 million U.S. adults2, often limiting daily life and work. SPR's FDA-cleared SPRINT® PNS System is a short-term, 60-day therapy designed to provide pain relief through a temporary treatment approach that does not require a permanent implant. The therapy integrates into existing clinical workflows and enables physicians to intervene earlier, expanding patient access."Our purpose first and foremost is to serve patients," said Domenico De Paolis, Interim President Neuromodulation, part of the Medtronic Neuroscience Portfolio. "That is why we continue to thoughtfully expand our pain intervention therapies. The addition of temporary peripheral nerve stimulation helps broaden access to neuromodulation and supports patients across more stages of the chronic pain journey with a minimally invasive therapy."The PNS segment continues to grow, driven by increasing clinical evidence, expanding reimbursement, and demand for non-opioid, less-invasive pain therapies. To date, the largest retrospective review of real-world PNS data, which includes more than 6,100 patients, was conducted using the SPRINT PNS System and showed over 71 percent of study participants demonstrated significant pain relief and/or improvement in quality of life following 60-day percutaneous PNS treatment3."Guided by our credo to advancing meaningful, patient-centered innovation in pain medicine, our agreement with Medtronic marks a pivotal step forward," said Maria E. Bennett, President and Chief Executive Officer of SPR Therapeutics. "Together, we will reach more patients helping them find relief earlier in their care journey to reclaim their lives and get back to what matters most."This transaction is subject to customary closing conditions and regulatory approvals. The anticipated close date will fall within the first half of Medtronic's Fiscal Year 2027, which officially began on April 25, 2026. Until closing, Medtronic and SPR Therapeutics will continue to operate as separate and independent companies.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit medtronic.com and follow us on LinkedIn.About SPR 
SPR is a medical technology company focused on advancing minimally invasive therapies for the treatment of pain. Its SPRINT® PNS System is designed to deliver short-term peripheral nerve stimulation therapy for sustained pain relief, supported by a growing body of clinical evidence and expanding reimbursement coverage. For more information on SPR Therapeutics, visit sprpainrelief.com and follow SPR on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.Medtronic Contacts:
Justin Paquette                 Ingrid Goldberg      Public Relations               Investor Relations         +1-612-271-7935             investor.relations@medtronic.comReferencesMedtronic SCS Value Summary FY25; Lo Bianco, G., et al. (2025). Barriers to neuromodulation. J Anesth Analg Crit Care, 5(1):3.American Chronic Pain Association. Pain Fact Sheet. Found at https://www.acpanow.com/uploads/9/9/8/3/99838302/pain_fact_sheet.pdfHuntoon, E. A., et al. (2023). A retrospective review of real-world outcomes following 60-day PNS for the treatment of chronic pain. *Pain Practice*. View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-intent-to-acquire-spr-therapeutics-inc-expanding-care-options-for-people-living-with-chronic-pain-302777023.htmlSOURCE Medtronic plc Original: Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain

Why Medtech Giants Are Quietly Paying Up for AI DiagnosticsApril 29, 2026 10:30 AM
PR Newswire (Canada)

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, April 29, 2026 /CNW/ -- USANewsGroup.com News Commentary – There's a quiet bidding war underway for AI diagnostics, and the price keeps climbing. The global AI in medical imaging market is on track to hit $2.20 billion in 2026, with a 34.8% growth rate baked in through 2033[1]. Q1 2026 healthcare M&A activity tells the same story: capital is rotating into AI-enabled platforms that already carry regulatory clearance, recurring revenue, and real clinical data behind them[2]. That description fits a short list of names worth knowing right now: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Medtronic (NYSE: MDT), Danaher (NYSE: DHR), Profound Medical (NASDAQ: PROF), and DexCom (NASDAQ: DXCM).







Hospitals are voting with their wallets too. A fresh C-suite survey shows 57% now rank AI clinical solutions as their top technology priority for 2026 to 2027, up from just 19% in 2023[3]. The FDA has made it clear that real-world clinical evidence is now central to clearing AI software, which is exactly why institutional buyers are paying a clinical validation premium for platforms that already have multi-site data behind them[4].VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) just picked up a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform, VMS+™ 4.0. The Edison Awards are widely considered one of the most prestigious innovation prizes in the world, often called "the Oscars of Innovation," and past Gold winners include Abbott, Medtronic, and Boston Scientific. For a small-cap medtech company out of Toronto, that is serious company to keep.The technology behind the award takes a standard 2D ultrasound scan and converts it into a detailed 3D model of the heart. The company says the results are comparable to a cardiac MRI, but without the million-dollar machine or the months-long wait list. VMS+™ 4.0 is already deployed in hospitals across the United States, Canada, the United Kingdom, and Europe, which is a key reason the Edison judges took notice. Their evaluation process places heavy weight on technologies that have moved past the pilot stage and into real clinical use.That momentum is showing up in VentriPoint's commercial pipeline. The company recently announced a collaboration with the Health Division of the Montecristo Group to roll out VMS+™ across Costa Rica's public and private hospital networks. The Montecristo Group's Hospital Metropolitano also has an existing relationship with Sanford Health, one of the largest healthcare systems in the United States. VentriPoint also recently partnered with First Light Health, an Indigenous-owned medical services company, to bring cardiac diagnostics to Indigenous and remote communities across Canada through a hub-and-spoke model. That program builds on an earlier partnership with the Nisga'a Valley Health Authority in northern BC. South of the border, the company signed a commercial agreement with LG Consulting Solutions targeting cardiac centres in Northern California."Being awarded Gold affirms that VMS™ 4.0 has reached that threshold, and reinforces our belief that our platform has significant room to grow as adoption accelerates and new applications emerge," said Hugh MacNaught, CEO of VentriPoint.VentriPoint holds regulatory approvals in the United States, Canada, and Europe. Its VMS+™ platform is vendor-agnostic, meaning it works with ultrasound equipment from any manufacturer, and is built on more than a decade of proprietary Knowledge Based Reconstruction technology. The core value proposition is MRI-grade cardiac imaging at a fraction of the cost, deployable anywhere a standard ultrasound machine already sits. With a growing global footprint, a validated technology platform, and independent recognition from one of the world's top innovation bodies, VentriPoint is positioning itself as a name to watch in precision health.CONTINUED… Read this and more news for VentriPoint Diagnostics at:  https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointOther industry developments and happenings in the market include:Medtronic (NYSE: MDT) completed its acquisition of CathWorks, a privately held medical device company focused on coronary artery disease diagnosis and treatment, for $585 million with potential additional earn-out payments. The deal follows a 2022 co-promotion agreement and brings the CathWorks FFRangio System, an AI-powered, drug-free, wire-free coronary assessment platform, into Medtronic's interventional cardiology portfolio."The acquisition of CathWorks significantly enhances Medtronic's interventional cardiology portfolio with an innovative system that empowers physicians with data-driven insights for the diagnosis and treatment of coronary artery disease," said Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business, part of the Cardiovascular Portfolio at Medtronic. "Through our global footprint, welcoming CathWorks to Medtronic will expand access to the transformative FFRangio technology for our customers and their patients worldwide."The FFRangio System recently demonstrated non-inferiority to wire-based physiology in the ALL-RISE randomized control trial, which enrolled more than 1,900 patients across 59 sites globally. The acquisition is expected to be immaterial to Medtronic's fiscal year 2027 earnings and neutral to accretive thereafter, continuing the company's strategy of targeted tuck-in acquisitions to strengthen its core franchises.Danaher (NYSE: DHR) reported first quarter 2026 results showing revenues of $6.0 billion, up 3.5% year-over-year, with non-GAAP adjusted diluted EPS growing 9.5% to $2.06. Operating cash flow reached $1.3 billion, supported by strength in Bioprocessing and better-than-expected Life Sciences performance."Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth," said Rainer M. Blair, President and CEO of Danaher. "On the top line, we continued on a steady recovery path with strength in Bioprocessing and better-than-expected performance in Life Sciences largely offsetting the impact of a lighter-than-typical Q1 respiratory season at Cepheid."Danaher raised its full year 2026 adjusted diluted EPS guidance to $8.35 to $8.55, up from prior guidance of $8.35 to $8.50, and expects full year core revenue growth of 3% to 6%. The company also announced its intention to acquire Masimo Corporation, a provider of pulse oximetry and patient monitoring solutions, citing opportunities to enhance performance through the Danaher Business System and its global scale.Profound Medical (NASDAQ: PROF) is highlighting its TULSA-PRO system across seven presentations at the 2026 Society of Interventional Radiology Annual Scientific Meeting in Toronto, April 11-15. The commercial-stage medical device company's AI-powered, MRI-guided TULSA Procedure treats prostate cancer and benign prostatic hyperplasia without incisions, eliminating procedural blood loss and overnight hospital stays while minimizing side effects such as urinary incontinence and erectile dysfunction."Our significant presence at SIR 2026 comes at an opportune time as leading iMRI procedures, including MRI-guided biopsy and TULSA, are poised to transform how unmet medical needs across the prostate disease spectrum are being addressed," said Arun Menawat, CEO and Chairman of Profound Medical. "Awareness and acceptance of the TULSA Procedure's strong clinical profile, as well as its potential to become the next mainstream treatment modality for most men with prostate disease, is growing."Presentations will feature data from the Level 1 post-market CAPTAIN randomized controlled trial comparing TULSA against robotic prostatectomy for intermediate-risk prostate cancer. Profound Medical also commercializes Sonalleve, an MRI-guided therapy addressing bone metastases pain palliation, uterine fibroids, and adenomyosis, with its technologies approved across major global markets including the United States, Europe, and Canada.DexCom (NASDAQ: DXCM) is showcasing new clinical evidence at the 19th annual Advanced Technologies and Treatments for Diabetes Conference in Barcelona, reinforcing the role of continuous glucose monitoring across all diabetes types. A multi-center primary care registry study showed that after one year of Dexcom G7 use, people with Type 2 diabetes not on insulin therapy saw significant improvements in A1C and weight management, while claims data linked Dexcom CGM initiation to meaningful reductions in DKA-related hospitalizations and emergency room visits in both children and adults with Type 1 diabetes."There is no better global stage than ATTD to showcase how we're shaping the future of glucose biosensing around the world," said Jake Leach, president and chief executive officer at DexCom. "The data presented at ATTD reinforces the need for Dexcom CGM to become the standard of care for all people with Type 2 diabetes, including those not using insulin."Beyond the clinical data, DexCom is presenting its near- and long-term product roadmap, including upcoming features for Dexcom G7, Dexcom G7 15 Day, and Stelo, its health and wellness offering. The company recently launched Dexcom G7 15 Day in the U.S. and continues expanding its Dexcom Academy HCP education platform across Europe and the Middle East.Further Reading: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripointCONTACT:
USA NEWS GROUP
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.coherentmarketinsights.com/industry-reports/ai-in-medical-imaging-market https://www.sikich.com/insight/q1-2026-healthcare-ma-market-update/ https://hitconsultant.net/2026/03/24/sage-growth-partners-health-it-purchasing-forecast-2026-2027-ai-roi/ https://www.fda.gov/news-events/fda-voices/real-world-evidence-advancing-regulatory-decision-making-medical-devices Logo - https://mma.prnewswire.com/media/2838876/5919929/USA_News_Group_Logo.jpg



View original content to download multimedia:https://www.prnewswire.com/news-releases/why-medtech-giants-are-quietly-paying-up-for-ai-diagnostics-302757277.html

Original: Why Medtech Giants Are Quietly Paying Up for AI Diagnostics

Medtronic announces CE Mark for Stealth AXiS™ surgical systemApril 28, 2026 4:00 AM
PR Newswire (US)

Following recent FDA clearances, Medtronic is accelerating access to integrated planning, navigation, and robotics platform across EuropeGALWAY, Ireland, April 28, 2026 /PRNewswire/ -- Medtronic, a global leader in healthcare technology, has received CE mark for the Stealth AXiS™ surgical system, a next-generation platform that brings planning, navigation, and robotics together into one single, intelligent system. The Stealth AXiS™ system is indicated for spine and cranial procedures, highlighting the platform's scalability across multiple surgical specialties for Medtronic.







"Receiving CE mark for the Stealth AXiS™ system marks an important milestone in expanding access to advanced surgical technologies across Europe," said Oli Prosperi, Vice President, International Commercial, Cranial & Spinal Technologies, Medtronic. "Achieving CE mark in the current regulatory environment, under EU Medical Device Regulation (MDR), underscores our commitment to bringing meaningful innovation into a highly diverse healthcare landscape." The Stealth AXiS™ system represents major advancement in surgical technology by integrating planning, navigation, and robotic execution into a single, modular platform. Designed to support a wide range of clinical workflows and surgical environments, the system enables hospitals to adopt capabilities based on their needs, while maintaining flexibility for future expansion.A key innovation of the system is LiveAlign™ segmental tracking, an industry-first capability that allows surgeons to visualize anatomical motion and patient alignment in real time during spine procedures. As a cornerstone of Medtronic's AiBLE™ ecosystem, the Stealth AXiS™ system connects pre-, intra-, and post-operative workflows, enabling a more integrated approach to surgical care.A key strength of the platform lies in its AI-driven architecture, which enables advanced planning and visualization across all stages of surgery - before, during, and after the procedure. In cranial applications, it features AI-powered automatic tractography, allowing surgeons to create patient-specific brain maps and clearly visualize critical neural pathways linked to essential brain functions."The introduction of the Stealth AXiS™ system to Europe reflects our focus on delivering connected platforms that improve precision, efficiency, and consistency across diverse healthcare systems," said Michael Carter, Senior Vice President and President of Cranial & Spinal Technologies at Medtronic. "By bringing planning, navigation, and robotic guidance into a unified workflow, we are helping surgeons translate insight into action in the operating room, supporting more predictable and personalized care while building a strong foundation for continued innovation."The CE mark follows U.S. FDA clearances earlier this year, highlighting Medtronic's ability to rapidly bring advanced surgical technologies to global markets.For more information about the Stealth AXiS™ surgical system and the AiBLE™ smart ecosystem, visit our website.About the Cranial & Spinal Technologies Business at Medtronic
As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, we serve over 4 million patients annually. Building on a legacy of innovation, our AiBLE™ ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and achieve better outcomes, before, during, and beyond surgery.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Contacts:
Maria Trenzado
Communications for Western Europe
maria.trenzado @LRoy-505-2696










View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-ce-mark-for-stealth-axis-surgical-system-302754990.htmlSOURCE Medtronic plc

Original: Medtronic announces CE Mark for Stealth AXiS™ surgical system

Medtronic Discloses Cybersecurity Incident Involving IT SystemsApril 27, 2026 11:22 AM
IH Market News
Medtronic (NYSE:MDT) said an unauthorized third party gained access to data within portions of its information technology systems on Thursday, prompting the company to take immediate action.The medical device manufacturer stated that it quickly contained the breach and initiated its established incident response procedures.



Investigation Underway With External Experts



Medtronic has brought in third-party cybersecurity specialists to assist with investigating the incident and implementing remediation measures. The company emphasized that there has been no identified impact on its products, patient safety, customer connectivity, or overall operations.



No Material Business Impact Expected



According to Medtronic, the breach is not anticipated to have a material effect on its business performance or financial results.



More about Medtronic



Medtronic is a global medical technology company that develops and manufactures devices and therapies used to treat a wide range of chronic diseases, with a focus on improving patient outcomes through innovation.Medtronic stock price

Original: Medtronic Discloses Cybersecurity Incident Involving IT Systems

Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continuesApril 25, 2026 12:30 PM
PR Newswire (US)

HRS late-breaking data: Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic ventricular tachycardia (VT)Breakthrough device designation granted for use of the Sphere-9 catheter for treatment of VT; U.S. pivotal trial approved by FDANew at HRS: data show consistent durability for the Sphere-360 catheter across patient anatomies; Sphere-360 approved in CE Mark geographiesFirst patients enrolled in Conquer-AF trial to evaluate the Sphere-9 catheter for repeat atrial fibrillation proceduresGALWAY, Ireland and CHICAGO, April 25, 2026 /PRNewswire/ -- Medtronic plc, (NYSE: MDT), a global leader in healthcare technology, today announced continued momentum for the Affera™ family of technologies for cardiac arrhythmia treatment, including promising data presented at the Heart Rhythm Society (HRS) Annual Meeting and the start of a new trial to evaluate a broader population of atrial fibrillation (AFib) patients. With ongoing positive physician feedback and global commercial expansion, Medtronic continues to invest in clinical research to study the Affera mapping and ablation system for potential new indications.Results from the ongoing early feasibility study evaluating the Affera mapping and ablation system and the Sphere-9™ catheter for treatment of recurrent sustained monomorphic ventricular tachycardia (VT) after a heart attack were presented as a late-breaking clinical trial. Patients treated at centers across the U.S. were followed for six months post-ablation. Results showed 65.5% of patients remaining free from VT recurrence at six months.1VT is a potentially life-threatening arrhythmia that causes the heart to beat abnormally fast. VT patients are treated with medications and often receive life-saving therapies from implanted defibrillators in the form of pacing or shocks.2 Catheter ablation for VT is an established treatment option; however, outcomes have remained suboptimal with little ablation tool innovation in recent years. As a result, a significant unmet need exists to improve patient care.3, 4  In recognition of this critical unmet need, the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the Sphere-9 catheter for the treatment of VT, providing an expedited regulatory pathway for the technology."Physicians urgently need better tools for VT that are safe, effective, and increase procedure efficiency, so it's exciting to see sustained outcomes for ischemic patients treated with the Affera mapping and ablation system and the Sphere-9 catheter after six months," said Vivek Reddy, M.D., Director of Cardiac Arrhythmia Services for the Mount Sinai Health System in New York City. "Moving this research forward to the IDE trial and expanding the patient population to include non-ischemic patients are positive next steps for VT patients."The Affera mapping and ablation system with the Sphere-9 catheter is an all-in-one, dual-energy pulsed field (PF) and radiofrequency (RF) ablation and high-definition mapping system for use in cardiac electrophysiology ablation procedures.Also at HRS, a new sub-analysis from the Sphere-360™ European study demonstrated positive results related to durability of lesions in AFib procedures in patients with left common pulmonary veins. Results showed 100% lesion durability, highlighting consistency across patients with varied anatomies. Previously reported durability data showed 98% per vein and 93% per patient durability through invasive remapping at 75 days post-ablation. The Sphere-360 catheter is an all-in-one mapping and single-shot pulsed field ablation (PFA) catheter for treatment of paroxysmal AFib that is approved in Europe and investigational in the U.S., with the U.S. IDE trial underway.Medtronic also announced the first patient enrollment in Conquer-AF, a prospective, multi-center, interventional, non-randomized study to characterize the safety and effectiveness of the Sphere-9 catheter in patients with recurrent paroxysmal or persistent AFib who have previously had an ablation procedure. The study is enrolling patients in the U.S., Europe, and Australia."Our robust clinical research program reinforces our commitment to advancing safe, effective, and efficient therapies to help physicians treat a wide range of cardiac arrhythmias and improve patients' lives," said Khaldoun Tarakji, M.D., MPH, vice president, chief medical officer, Cardiac Ablation Solutions business, which is part of the Cardiovascular Portfolio at Medtronic. "The encouraging results shown in this VT study underscore the versatility of the Sphere-9 catheter in treating a variety of different arrhythmias and the potential to advance care and outcomes for patients whose disease is often complex. With the Sphere-360 catheter, consistent durability across a wide range of patient anatomies is good news for patients and for physicians' workflow."The Sphere-9 catheter is approved in multiple geographies including the U.S., Europe, Australia, and Japan. Indications vary by geography. The Sphere-9 catheter is not approved for VT in any geography. The Sphere-360 catheter received CE Mark in January 2026, and the Horizon 360 IDE trial is enrolling patients in the U.S.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Reddy VY, et al. Six-month outcomes from the Sphere-9 ventricular tachycardia early feasibility study: Dual-energy lattice-tip mapping and ablation catheter for ventricular tachycardia treatment. Late-Breaking Clinical Trial, Heart Rhythm Society Annual Meeting, April 25, 2026; Chicago IL.Sciria,C. et al. Trends and Outcomes of Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic and Nonischemic Cardiomyopathy. Circ: Arr. and Elec. 2022; vol.15, no. 4.Cronin EM, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. EP Europace. 2019 Aug 1;21(8):1143-4.Zeppenfeld K, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126.Dr. Reddy is a paid consultant for Medtronic.Contacts:Leslie Williamson                               
Public Relations                                 
+1-612-227-5099                                Ingrid Goldberg
 Investor Relations
+1-763-505-2696 





View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-key-affera-clinical-study-milestones-for-sphere-9-and-sphere-360-catheters-as-global-adoption-continues-302753436.htmlSOURCE Medtronic plc

Original: Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues

Medtronic to announce financial results for its fourth quarter and full fiscal year 2026April 13, 2026 6:00 AM
PR Newswire (US)

GALWAY, Ireland, April 13, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Wednesday, June 3, 2026, for its fourth quarter and full fiscal year 2026, which ends on Friday, April 24, 2026.A news release containing summary financial information will be issued at 5:45 a.m. Central Time (CT) and will be available at https://news.medtronic.comA video webcast to discuss results will begin at 6:45 a.m. CT and can be accessed at https://investorrelations.medtronic.comWithin 24 hours of the video webcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at https://investorrelations.medtronic.com.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Contacts:
Justin Paquette
Public Relations
+1-612-271-7935Ingrid Goldberg
Investor Relations
+1-763-505-2696





View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-to-announce-financial-results-for-its-fourth-quarter-and-full-fiscal-year-2026-302739997.htmlSOURCE Medtronic plc

Original: Medtronic to announce financial results for its fourth quarter and full fiscal year 2026

Medtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT ProceduresMarch 27, 2026 9:00 AM
PR Newswire (US)

GALWAY, Ireland, March 27, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system for cranial and ear, nose, and throat (ENT) procedures. Cleared for spine procedures in February, the Stealth AXiS™ surgical system unifies surgical planning, navigation, and robotics into a single intelligent system to support surgeons with greater precision and real-time insights during complex procedures. This clearance reinforces Medtronic's strategy to deliver connected technologies that support surgeons across multiple specialties on a single platform."Cranial procedures require an exceptional level of precision, planning, and real-time insight," said Michael Carter, Senior Vice President and President of Medtronic Cranial & Spinal Technologies. "With the Stealth AXiS™ surgical system, we are bringing together advanced navigation, robotics, and AI-enabled capabilities within the AiBLE™ smart ecosystem to support surgeons with deeper insights across the surgical workflow."A defining capability of the platform is its AI-enabled architecture, which supports advanced planning and visualization before, during, and after surgery. For cranial procedures, the system includes AI-based automatic tractography that helps surgeons generate patient-specific brain maps and visualize critical neural pathway associated with essential brain functions. The platform also integrates intraoperative ultrasound through GE HealthCare's bkActiv™, providing additional real-time imaging during procedures."For complex brain surgeries, the more information you have, the better decisions you can make," said Dr. Michael Ivan, neurosurgeon at the University of Miami Health System. "Pre-operative planning with tools like tractography may help surgeons enhance surgical efficiency and support better patient outcomes." 1,2For ENT procedures, the Stealth AXiS™ surgical system delivers high-precision navigation and advanced visualization tailored to the intricate anatomy of the sinuses and skull base. Built around real-world ENT workflows, the system offers sharper anatomical detail and faster responsiveness to support confident decision-making in the OR, as well as intuitive, surgeon-centered workflows to create a familiar user experience while delivering enhanced capabilities."Intraoperative navigation is critical in minimally invasive endoscopic surgery of the sinuses and skull base, helping surgeons confidently delineate complex anatomy within high-risk spaces," said Dr. Vijay Ramakrishnan, board-certified otolaryngologist and professor of Otolaryngology-Head & Neck Surgery at Indiana University School of Medicine. "The Stealth AXiS™ system leverages innovative technologies to enhance surgeon workflows and support procedural efficiency and confidence in the operating room."Additionally, the system's flexible architecture is designed to support continuous software innovation, expanded capabilities, and deeper ecosystem connectivity to help shape the next era of surgery."The Stealth AXiS™ surgical system represents the next era of navigation for ENT surgery," said Sean Haag, President of the Ear, Nose, & Throat business at Medtronic. "Building on 25 years of navigation leadership, this system is designed to help surgeons move with greater clarity, confidence, and control in the OR, while creating a powerful platform for the next generation of ENT innovation."For more information about the Stealth AXiS™ surgical system and the AiBLE™ smart ecosystem, visit www.medtronic.com/stealthaxis.About the Cranial & Spinal Technologies Business at Medtronic
As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, we serve over 4 million patients annually. Building on a legacy of innovation, our AiBLE™ ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and achieve better outcomes, before, during, and beyond surgery.About the Ear, Nose, & Throat Business at Medtronic
Medtronic's Ear, Nose, and Throat (ENT) business is the global market leader in ENT, delivering innovative technologies that impact nearly 3 million patients each year. For more than 25 years, we have partnered with physicians to advance care across the specialty. Our portfolio supports surgical procedures related to chronic rhinosinusitis and head and neck cancers, spanning surgical navigation, tissue health, powered instruments, localized drug delivery, intraoperative nerve monitoring, and parathyroid detection. As the global leader in ENT navigation since the introduction of the LandmarX™ image-guided surgery system in 1998, we continue to advance the field with next-generation platforms including the Stealth AXiS™ Surgical System.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Contacts:
Christine Stewart
Public Relations
+1-269-377-2557Ingrid Goldberg
Investor Relations
+1-763-505-26961Li Z, et al. World Neurosurgery. 2018;116:e291-e297. 2 Guberman GI, et al. Neurology. 2025;105(9).





View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-receives-fda-clearance-for-stealth-axis-surgical-system-for-cranial-and-ent-procedures-302727270.htmlSOURCE Medtronic plc

Original: Medtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT Procedures

Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular careMarch 10, 2026 6:45 AM
PR Newswire (US)

Deal complements Medtronic's Neurovascular portfolio, delivering simplicity and access when 'time is brain'GALWAY, Ireland, March 10, 2026 /PRNewswire/ -- Medtronic today announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative technology across the neurovascular portfolio. The acquisition is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition.Scientia is a private company operating in Salt Lake City, Utah, with approximately 310 employees. Under founder and current chief technology officer John Lippert, the company has developed best-in-class access products that enable simplicity and access for physicians treating complex neurovascular conditions. Scientia's portfolio of guidewires and catheters can be seamlessly integrated with Medtronic's existing suite of neurovascular products, strengthening the company's ability to support physicians across the full procedural workflow.In stroke treatment, every second matters. With each second of restricted blood flow, the brain loses millions of brain cells. Today, stroke is the third leading cause of death and leading cause of disability worldwide. Unlike vessels in many other parts of the body, cerebral vasculature is highly complex and tortuous, creating significant challenges for physicians attempting to reach the site of an occlusion or aneurysm. Difficult access can delay therapy delivery and impact procedural success.Scientia's novel access platform is designed to address these challenges by improving navigability through complex anatomy and simplifying neurovascular procedures. By enabling faster and more reliable access, these technologies improve procedural efficiency."Medtronic is thrilled to acquire Scientia to accelerate meaningful innovation in neurovascular care," said Linnea Burman, senior vice president and president of Medtronic's Neurovascular business, which is part of the Neuroscience Portfolio at Medtronic. "This acquisition positions Medtronic with a full suite of products. It builds a strong foundation for Medtronic and supports procedures across both hemorrhagic and acute ischemic stroke. Medtronic's best-in-class therapies, combined with Scientia's leading access portfolio, will be incredibly powerful. With 12 million people globally suffering from stroke each year, we look forward to contributing to better patient outcomes around the world." "As a company committed to improving patients' lives, we are humbled and excited for what's ahead," said Rick Randall, CEO, Scientia. "Scientia has developed critical technology that has been embraced by physicians. This deal allows us to take our engineering into disease states globally and positions Medtronic with a comprehensive portfolio and complete guidewire line. With the size and scale of Medtronic, the opportunity to treat more patients and drive more impact is truly exciting.""Microwires and microcatheters are required for all neurointerventional cases," said Dr. David Fiorella, director of the Cerebrovascular Center at Stony Brook Medicine. "Correspondingly, better microwires and microcatheters make every single case technically easier, faster and ultimately safer for patients. This revolutionary microwire technology has enabled – and will continue to enable – access and simplify the neurovascular procedures we do."This acquisition is expected to close in the first half of FY27, subject to regulatory approvals and satisfaction of other closing conditions. It is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and accretive thereafter.About the Neurovascular Business at Medtronic 
Medtronic helped create the neurovascular market – introducing innovations like liquid embolic, stent retrievers, and flow diverters. Today, with products covering multiple conditions and disease states, we work to eliminate the burden of stroke and other neurovascular diseases globally by transforming care, one breakthrough at a time. Together with our partners, including physicians, hospitals, governments and patients, we're expanding into new disease states and stages of care. Our unwavering focus on better outcomes fuels our drive to deliver life-changing therapies and transform the future of care for patients worldwide. For more information, follow Medtronic Neurovascular on LinkedIn.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Contacts:Erika Winkels Ingrid GoldbergPublic Relations Investor Relations+1-612-558-8932 +1-612-505-2696  





View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-to-acquire-scientia-vascular-marrying-access-and-therapeutic-portfolios-for-neurovascular-care-302708767.htmlSOURCE Medtronic plc

Original: Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care

MiniMed to begin trading on Nasdaq Global Select MarketMarch 6, 2026 9:00 AM
PR Newswire (US)

GALWAY, Ireland, March 6, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that MiniMed Group, Inc. (Nasdaq: MMED) will begin trading today on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol "MMED" in connection with its initial public offering ("IPO")."Today marks an exciting milestone for both MiniMed and Medtronic. Despite a challenging market backdrop shaped by geopolitical uncertainty, the teams successfully executed an oversubscribed offering and the second largest IPO in Medtech history," said Geoff Martha, Medtronic chairman and chief executive officer. "Establishing MiniMed as a standalone entity positions the company to operate with greater agility over the long term. At the same time, this transaction supports Medtronic's strategy to focus capital and resources on long term value creation opportunities that leverage our scale, synergies, and core competencies. We congratulate Que Dallara and our Diabetes colleagues whose leadership and dedication made this moment possible."About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.Medtronic ContactsJustin Paquette
Public Relations
+1-612-271-7935Ingrid Goldberg
Investor Relations
+1-763-505-2696 





View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-to-begin-trading-on-nasdaq-global-select-market-302706699.htmlSOURCE Medtronic plc

Original: MiniMed to begin trading on Nasdaq Global Select Market

MiniMed announces pricing of initial public offeringMarch 5, 2026 7:35 PM
PR Newswire (US)

GALWAY, Ireland and NORTHRIDGE, Calif., March 5, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a subsidiary of Medtronic plc (Medtronic) (NYSE: MDT), today announced the pricing of its initial public offering (IPO) of 28,000,000 shares of its common stock at a price to the public of $20.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market (Nasdaq) on March 6, 2026, under the symbol "MMED." The offering is expected to close on March 9, 2026, subject to customary closing conditions.MiniMed has granted the underwriters a 30-day option to purchase up to 4,200,000 additional shares of common stock at the initial price to the public, less underwriting discounts and commissions. Upon completion of the IPO, Medtronic is expected to hold approximately 90.03% of MiniMed, or 88.70% if the underwriters exercise their over-allotment option in full. MiniMed intends to use a portion of the net proceeds from this offering for general corporate purposes. The remainder, if any, will be used to repay intercompany debt owed to Medtronic and as additional consideration to Medtronic for certain assets transferred to MiniMed in the separation.Goldman Sachs & Co. LLC, BofA Securities, Citigroup and Morgan Stanley are acting as the active bookrunners for the proposed offering. Barclays, Deutsche Bank Securities, Mizuho, Wells Fargo Securities, Evercore ISI and Piper Sandler are also acting as joint book running managers and BTIG and William Blair & Company, L.L.C. are acting as co-managers. The offering will be made only by means of a prospectus. When available, copies of the prospectus relating to the IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at +1-866-471-2526, by facsimile at +1-212-902-9316 or by email at prospectus-ny @shazaam-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, by email at dg.prospectus_requests@bofa.com; Citigroup, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, telephone at +1-800-831-9146; and Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com.A registration statement on Form S-1 relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (SEC). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the offering and the use of proceeds therefrom. There are significant risks and uncertainties relating to the IPO. Important factors that could cause actual results to differ materially from management's expectations include, without limitation: the satisfaction of customary closing conditions relating to the IPO; capital market risks; and the impact of general economic or industry conditions. There can be no guarantees that MiniMed or Medtronic will achieve the anticipated benefits of the IPO. The ability of MiniMed or Medtronic to achieve the anticipated benefits of the IPO may be materially affected by such factors as changes to the business, results of operations or financial condition of MiniMed or Medtronic, changes in the medical products industry, adverse market or macroeconomic conditions and other factors outside the control of MiniMed or Medtronic. For additional information about the factors that affect Medtronic's and MiniMed's businesses, please see their respective filings with the SEC. Each of Medtronic and MiniMed does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.Medtronic Contacts
Justin Paquette
Public Relations
+1-612-271-7935Ingrid Goldberg
Investor Relations
+1-763-505-2696 





View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-announces-pricing-of-initial-public-offering-302706144.htmlSOURCE Medtronic plc

Original: MiniMed announces pricing of initial public offering

Medtronic CFO Thierry Piéton to speak at upcoming investor conferencesMarch 3, 2026 10:31 AM
PR Newswire (US)

GALWAY, Ireland, March 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that Thierry Piéton, Medtronic executive vice president and chief financial officer, will participate in fireside chats at the following investor conferences:Barclays 28th Annual Global Healthcare Conference
Tuesday, March 10, 2026, at 10:30 a.m. a.m. EST (9:30a.m. CST)Leerink Partners Global Healthcare Conference
Wednesday, March 11, 2026 at 9:20 a.m. EST (8:20 a.m. CST).A live webcast for each session will be available on the date and time of each of the conferences noted above by clicking on the Investors Events link at: http://investorrelations.medtronic.com. An archive session will be available on the same webpage later in the day.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Contacts
Contacts:
Justin Paquette
Public Relations
+1-612-271-7935Ingrid Goldberg
Investor Relations
+1-763-505-2696 





View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-cfo-thierry-pieton-to-speak-at-upcoming-investor-conferences-302702659.htmlSOURCE Medtronic plc

Original: Medtronic CFO Thierry Piéton to speak at upcoming investor conferences

Medtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensorFebruary 25, 2026 8:30 AM
PR Newswire (US)

Real-time actionable insights on one mobile app for people who manage their diabetes using multiple daily injectionsGALWAY, Ireland, Feb. 25, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the commercial launch in Europe of the MiniMed Go™ Smart MDI system with the Simplera™ sensor. The system, which is the first and only solution to integrate data from the InPen™ smart insulin pen and the Simplera™ sensor into a single mobile app, is designed to help people who use multiple daily injections (MDI) to better control their diabetes. The launch will be rolled out gradually across Europe starting this month.







The MiniMed Go™ Smart MDI system marks a departure from traditional and basic connected insulin pens. It provides real-time, personalized insights, actionable dose alerts, a built-in advanced dose calculator, and continuous guidance — all accessible through a smartphone app. This intelligent decision support tool aims to address daily challenges faced by those managing diabetes with MDI.Missing insulin doses (boluses) can significantly impact glycemic control. Research shows that skipping just two doses per week may increase HbA1C by up to 0.4,1 raising the risk of both short- and long-term complications.2 Another study found that missing two basal doses or four bolus doses over 14 days was linked to more than a 5% decrease in Time in Range.3 Real-world data 4 from the previous generation of the Medtronic Smart MDI system demonstrated that users who responded to more than 75% of missed dose alerts within one hour achieved Time in Range (TIR) of 67.2% compared to the mean TIR for the cohort at 55.7%, and up to 71.5% TIR when addressing high blood sugar alerts."Real-time actionable alerts are becoming the key to better clinical outcomes for people with diabetes using multiple daily injections," said Que Dallara, EVP and president of Medtronic Diabetes and CEO-designate of MiniMed. "The MiniMed Go™ system remembers, reminds and recommends the right dose at the right time so you don´t have to." †For busy healthcare professionals, the MiniMed Go™ system includes new CareLink Clinic MDI reports, that make it easier for clinicians to interpret user data and support more informed patient discussions. "Smart MDI has fundamentally changed how we care for patients on multiple daily injections," said Dr Martín Cuesta Hernández, Endocrinologist, Hospital Clinico San Carlos - Madrid, Spain. "We're now making evidence-based decisions instead of relying on assumptions, which has strengthened trust and improved the quality of our conversations with patients. Many people simply tell us they're delighted because life is easier. Combined with efficient telemedicine delivery, we're able to provide more personalised, effective care than ever before."In Europe, the MiniMed Go™ system with Simplera™ sensor is approved for people with insulin-requiring diabetes aged 7 years and older, as well as for children aged 2 to 6 years under the supervision of an adult caregiver. Compatibility of the Instinct Go™ sensor, made by Abbott, with MiniMed Go™ in Europe is currently pending CE mark approval. Once approved, users will have the choice between a 7-day or 15-day sensor depending on what best fits their needs.Frequently Asked Questions
Q: What is the MiniMed Go™ system?
A: In Europe, the MiniMed Go™ system is a smart diabetes management solution that connects the InPen™ smart insulin pen with the Simplera™ sensor through the single MiniMed Go™ app. It provides real-time glucose data, dose calculations, missed dose alerts, and actionable guidance, making MDI therapy easier and more connected. CE mark approval is pending on integration with the Instinct Go™ sensor made by Abbott. In the U.S., the MiniMed Go™ Smart Multiple Daily Injection (MDI) system seamlessly integrates the InPen™ smart insulin pen with the Instinct sensor. Compatibility of the Simplera™ sensor with MiniMed Go™ is currently under FDA review.Q: What is InPen™? 
A: The InPen™ is a reusable smart insulin pen that uses Bluetooth® technology to send dose information to a mobile app. Offering dose calculations and tracking, InPen™ helps take some of the mental math out of diabetes management.Q: What's the difference between the MiniMed Go™ Smart MDI system and the previous Medtronic Smart MDI system with Simplera™ sensor?
A: There are a few upgrades including a single unified mobile app experience, easier onboarding, support and self-training tools, new features and insulin settings. For healthcare professionals, new CareLink Clinic dedicated MDI reports turn patient data into clinical and behavioural insights, making consultations more efficient.Q: What is the difference between the MiniMed Go™ Smart MDI system and traditional pens or other connected pens for diabetes?
A: Unlike traditional insulin pens, which lack the ability to track doses or provide decision support, the MiniMed Go™ Smart MDI system offers integration of real-time continuous glucose monitoring, a built-in dose calculator that simplifies dose decision-making, and smart dosing alerts to help people with their diabetes therapy adherence – the first and only Smart MDI system to offer an all in one mobile app.† Proper settings, connectivity, and some manual logging required. See user guides for full details and important safety information.The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.About the Diabetes Business at Medtronic
Medtronic Diabetes is on a mission to make diabetes more predictable with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront. About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Contacts:
Janet Cho
Public Relations
+1-818-403-7028Ingrid Goldberg
Investor Relations
+1-763-505-26961Randlov, J, Poulsen, JU. How Much Do Forgotten Insulin Injections Matter to Hemoglobin A1c in People with Diabetes, J Diabetes Sci Technol. 2008; 2(2):229-235.2American Diabetes Association Professional Practice Committee for Diabetes. Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan3Danne TPA, Joubert M, Hartvig NV, Kaas A, Knudsen NN, Mader JK. Association Between Treatment Adherence and Continuous Glucose Monitoring Outcomes in People With Diabetes Using Smart Insulin Pens in a Real-World Setting. Diabetes Care. 2024 Jun 1;47(6):995-1003. doi: 10.2337/dc23-2176. PMID: 38569055; PMCID: PMC11116913.4Laurenzi A, Edd SN, Adolfsson P, et al. Insights into the effective use of the Smart MDI system: Data from the first 1852 type 1 diabetes users. Diabet Med. 2025;42(12):e70161. doi:10.1111/dme.70161. 














View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-begins-emea-commercial-launch-of-minimed-go-smart-mdi-system-with-simplera-sensor-302697034.htmlSOURCE Medtronic plc

Original: Medtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor

MiniMed announces launch of IPO roadshowFebruary 24, 2026 8:30 AM
PR Newswire (US)

GALWAY, Ireland, Feb. 24, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a subsidiary of Medtronic plc (Medtronic) (NYSE: MDT), today announced that it has launched a roadshow for the initial public offering (IPO) of 28,000,000 shares of its common stock. The proposed offering is part of Medtronic's previously announced plan to separate its Diabetes business into an independent public company.The IPO price is currently expected to be between $25.00 and $28.00 per share. The underwriters will also be granted a 30-day option to purchase up to an additional 4,200,000 shares at the IPO price, less underwriting discounts and commissions. MiniMed expects to list its common stock on the Nasdaq Global Select Market (Nasdaq) under the symbol "MMED."Upon completion of the IPO, Medtronic will hold approximately 90.03% of MiniMed (or 88.70% if the underwriters exercise their over-allotment option in full). MiniMed intends to use a portion of the net proceeds from this offering for general corporate purposes. The remainder, if any, will be used to repay intercompany debt owed to Medtronic and as additional consideration to Medtronic for certain assets transferred to MiniMed in the separation. A registration statement on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations, or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. References to Medtronic plc and MiniMed Group, Inc., herein may refer to their subsidiaries, respectively.Goldman Sachs & Co. LLC, BofA Securities, Citigroup and Morgan Stanley are acting as the active bookrunners for the proposed offering. Barclays, Deutsche Bank Securities, Mizuho, Wells Fargo Securities, Evercore ISI and Piper Sandler & Co. are also acting as joint book running managers and BTIG and William Blair & Company, L.L.C. are acting as co-managers. The proposed offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the proposed IPO may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at +1-866-471-2526, by facsimile at +1-212-902-9316 or by email at prospectus-ny @shazaam-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, by email at dg.prospectus_requests@bofa.com; Citigroup, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, telephone at +1-800-831-9146; and Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com.About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to Medtronic's ability to satisfy the necessary conditions to consummate the separation of its Diabetes business on a timely basis or at all, Medtronic's ability to successfully separate its Diabetes business and realize the anticipated benefits from the separation (including consummating the transaction on a basis that is generally tax-free to shareholders), MiniMed's ability to succeed as a standalone publicly traded company, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances. While a split-off is the company's current preferred separation structure, a final decision has not been reached at this time. The separation is expected to occur through a series of capital markets transactions, which may include a spin-off, split-off, offering, or combination thereof, of the company's remaining shareholding in MiniMed. MiniMed Contacts
Janet Cho
Public Relations
+1-818-403-7028Ryan Weispfenning
Investor Relations
+1-763-505-4626 Medtronic Contacts
Justin Paquette
Public Relations
+1-612-271-7935Ingrid Goldberg
Investor Relations
+1-763-505-2696





View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-announces-launch-of-ipo-roadshow-302695244.htmlSOURCE Medtronic plc

Original: MiniMed announces launch of IPO roadshow

Medtronic tops Q3 forecasts with strongest revenue growth in 10 quartersFebruary 17, 2026 10:15 AM
IH Market News
Medtronic plc (NYSE:MDT) reported fiscal third-quarter 2026 results that exceeded analyst expectations, posting revenue of $9.0 billion. Sales rose 8.7% on a reported basis and 6.0% organically compared with the same period a year earlier.Adjusted earnings per share came in at $1.36, ahead of the $1.34 consensus estimate, while revenue also surpassed forecasts of $8.89 billion. The company noted that the quarter delivered its highest enterprise revenue growth in the past 10 quarters. Shares slipped 0.5% following the announcement.The Cardiovascular Portfolio led performance, with revenue climbing 13.8% as reported and 10.6% organically to $3.46 billion. Within that segment, Cardiac Ablation Solutions stood out, recording 80% global growth and a 137% increase in the U.S., supported by strong uptake of its pulsed field ablation products.“Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance, demonstrating the strength of our portfolio,” said Geoff Martha, Medtronic chairman and chief executive officer. “By unlocking new markets and investing in high-growth opportunities, we are accelerating performance across the company.”Elsewhere, the Neuroscience Portfolio rose 4.1% as reported to $2.56 billion, the Medical Surgical Portfolio advanced 4.9% to $2.17 billion, and the Diabetes segment grew 14.8% to $796 million.Medtronic reaffirmed its fiscal 2026 outlook, maintaining expectations for approximately 5.5% organic revenue growth and adjusted EPS between $5.62 and $5.66. The guidance factors in a potential $185 million impact from tariffs.Medtronic stock price

Original: Medtronic tops Q3 forecasts with strongest revenue growth in 10 quarters

Medtronic announces first surgery with Hugo™ robotic-assisted surgery system in the U.S. performed at Cleveland ClinicFebruary 17, 2026 6:44 AM
PR Newswire (US)

Newly FDA-cleared system helps expand patient access to minimally invasive surgeryCleveland Clinic joins nationally recognized academic medical centers including Atrium Health Wake Forest Baptist High Point Medical Center as first hospitals in the U.S. to install Hugo RAS systemGALWAY, Ireland, Feb. 17, 2026 /PRNewswire/ -- Medtronic today announced that the first U.S. commercial surgical case using its recently FDA-cleared Hugo™ robotic-assisted surgery (RAS) system has been successfully performed by Jihad Kaouk, MD, professor and chair of the Glickman Urologic Institute and the Zegarac-Pollock Endowed Chair in Robotic Surgery at Cleveland Clinic.Dr. Kaouk successfully completed a robotic-assisted prostatectomy, and the patient was discharged the day after surgery."This case exemplifies Cleveland Clinic's mission to lead surgical innovation and expand access to minimally invasive surgery," said Dr. Kaouk. "The new technology allows us to customize the approach for each patient case."Urology has led the way in adoption of robotic technology, with about 80% of urologic abdominal surgeries in the U.S. today conducted with the assistance of a robotic system. This high adoption rate has created a community of surgeons highly experienced in robotic-assisted procedures available to support training as new technology like the Hugo RAS system becomes available, which is important as robotic-assisted approaches are increasingly common across many specialties and hospitals are looking for solutions to address capacity challenges.The Hugo RAS system's mobile footprint with modular arms may help address operating room scheduling challenges and infrastructure limitations, enabling more patients access to the well-documented benefits of minimally invasive care — including reduced blood loss, shorter hospital stays, decreased recovery time, and less postoperative pain.†,1-3Cleveland Clinic actively researches and implements new robotic approaches. Their team, led by Dr. Kaouk as the Principal Investigator, was part of the Expand URO Investigational Device Exemption (IDE) clinical study — the largest ever completed for multi-port robotic-assisted urological surgery in the U.S. Expand URO demonstrated that the Hugo RAS system met primary safety and effectiveness endpoints in urologic surgical procedures, with outcomes that are consistent with published literature."We are excited that the first commercial case in the U.S. using the Hugo RAS system has been successfully completed by Dr. Kaouk and his team. Their pioneering spirit and collaboration reflect our shared vision that with new technology, like Hugo, more patients can access the benefits of minimally invasive surgery," said Rajit Kamal, vice president and general manager of Robotic Surgical Technologies within the Surgical business of Medtronic. "The future of surgery isn't about robotics as a separate modality, it's about technology that enables surgical teams to deliver the best possible care for every patient. Medtronic is uniquely positioned to do that as the only company in the world that can partner with surgeons and hospitals across open, laparoscopic, and robotic-assisted surgery."In addition to Cleveland Clinic, Duke University Hospital and Atrium Health Wake Forest Baptist High Point Medical Center are among the first hospitals in the U.S. to install the Hugo RAS system. Atrium Health Wake Forest Baptist High Point Medical Center is the first hospital in the country to install the Hugo RAS system that was not part of the IDE clinical study.The Hugo RAS system represents an advancement in surgical robotics in the U.S., offering surgeons a flexible, accessible alternative that prioritizes choice, collaboration, and efficiency in the operating room. The Hugo RAS system is available for use in more than 35 countries around the world. The introduction of the Hugo RAS system in the U.S. builds on Medtronic's broad surgical offering, including the Touch Surgery™ ecosystem, to deliver a connected, integrated operating room — today and in the future.The company plans to follow its initial urology indication for the Hugo™ RAS system with indication expansion into gynecologic and general surgery procedures, including hernia repair.For more information, visit medtronic.com/hugoishere.†Compared to open surgery.Fitch K, Engel T, Bochner A. Cost differences between open and minimally invasive surgery. Managed Care. 2015;24(9):40–48.Tiwari MM, Reynoso JF, High R, Tsang AW, Oleynikov D. Safety, efficacy, and cost effectiveness of common laparoscopic procedures. Surg Endosc. 2011;25(4):1127-1135.Roumm AR, Pizzi L, Goldfarb NI, Cohn H. Minimally invasive: minimally reimbursed? An examination of six laparoscopic surgical procedures. Surg Innov. 2005;12(3):261–287.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Contacts:
Gary Jeanfaivre
Public Relations
+1-203-556-0777Ingrid Goldberg
Investor Relations
1-763-505-2696










View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-first-surgery-with-hugo-robotic-assisted-surgery-system-in-the-us-performed-at-cleveland-clinic-302689203.htmlSOURCE Medtronic plc

Original: Medtronic announces first surgery with Hugo™ robotic-assisted surgery system in the U.S. performed at Cleveland Clinic

Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quartersFebruary 17, 2026 6:45 AM
PR Newswire (Canada)

Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolioGALWAY, Ireland, Feb. 17, 2026 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its third quarter (Q3) of fiscal year 2026 (FY26), which ended January 23, 2026.Q3 Key HighlightsRevenue of $9.0 billion, increased 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidanceGAAP diluted EPS of $0.89; non-GAAP diluted EPS of $1.36, three cents ahead of Q3 guidance mid-pointCompany reiterates FY26 organic revenue growth and EPS guidanceCardiac Ablation Solutions revenue increased 80%, including 137% in the U.S., on strength of pulsed field ablation (PFA) portfolioSecured CE Mark for Sphere-360™ and initiated U.S. pivotal trialSecured U.S. FDA clearance for Hugo™ robotic-assisted surgery; first cases completed this monthSecured U.S. FDA clearance for Stealth AXiS™ Surgical System for spinal proceduresDiabetes revenue increased 8.3% led by double-digit strength in International marketsExecuting M&A strategy with two key transactions in the quarter: CathWorks in Coronary and Renal Denervation and Anteris in Structural Heart"Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance, demonstrating the strength of our portfolio," said Geoff Martha, Medtronic chairman and chief executive officer. "By unlocking new markets and investing in high-growth opportunities, we are accelerating performance across the company. Our innovation pipeline and portfolio breadth give us confidence in our ability to sustain long-term growth. It's an exciting time for Medtronic."Financial Results
Medtronic reported Q3 worldwide revenue of $9.017 billion, an increase of 8.7% as reported and 6.0% on an organic basis. The organic revenue growth comparison excludes:Other revenue of $32 million in the current year and $32 million in the prior yearRevenue from the Dutch Obesity Clinic (NOK) divestiture with no revenue in the current year and $15 million in the prior yearForeign exchange benefit of $242 million on the remaining segmentsQ3 revenue by segment included:Cardiovascular Portfolio revenue of $3.457 billion, an increase of 13.8% as reported and 10.6% organic, with high-teens increase in Cardiac Rhythm & Heart Failure, low-single digit increase in Structural Heart & Aortic, and mid-single digit increase in Coronary & Peripheral Vascular, all on an organic basisNeuroscience Portfolio revenue of $2.558 billion, an increase of 4.1% reported and 2.5% organic, with mid-single digit increase in Neuromodulation, mid-single digit increase in Cranial & Spinal Technologies, and flat result in Specialty Therapies, all on an organic basisMedical Surgical Portfolio revenue of $2.173 billion, an increase of 4.9% as reported and 2.7% organic, with low-single digit increase in Surgical & Endoscopy, and high-single digit increase in Acute Care & Monitoring, all on an organic basisDiabetes business revenue of $796 million, an increase of 14.8% as reported and 8.3% organicQ3 GAAP operating profit and operating margin were $1.464 billion and 16.2%, respectively. As detailed in the financial schedules included at the end of the release, Q3 non-GAAP operating profit and operating margin were $2.177 billion and 24.1%, respectively.Q3 GAAP net income and diluted earnings per share (EPS) were $1.143 billion and $0.89, respectively. As detailed in the financial schedules included at the end of this release, Q3 non-GAAP net income and non-GAAP diluted EPS were $1.750 billion and $1.36, respectively.Guidance
The company reiterates its FY26 organic revenue growth of approximately 5.5% and diluted non-GAAP EPS guidance of $5.62 to $5.66. This includes a potential impact from tariffs of approximately $185 million, unchanged from the prior guidance. Excluding the potential impact from tariffs, this guidance represents FY26 diluted non-GAAP EPS growth of approximately 4.5%."This quarter, we again delivered accelerated growth while investing decisively in our future," said Thierry Piéton, Medtronic chief financial officer. "We continued to invest in R&D to strengthen our innovation pipeline, funded significant growth opportunities while driving G&A leverage, and we executed on our M&A and venture strategy with two key transactions in the quarter. Bottom line, we are executing on our roadmap and positioning the business for sustainable growth."Video Webcast Information
Medtronic will host a video webcast today, February 17, at 8:00 a.m. EST (7:00 a.m. CST) to provide information about its business for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Quarterly Earnings icon at investorrelations.medtronic.com, and this earnings release will be archived at news.medtronic.com. Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Past Events and Presentations link under the News & Events drop-down at investorrelations.medtronic.com.Financial Schedules and Earnings Presentation
The third quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Quarterly Earnings link at investorrelations.medtronic.com. To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here. To view the earnings presentation, click here.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow on LinkedIn.FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, material acquisition and divestiture transactions, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.NON-GAAP FINANCIAL MEASURES
This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. References to quarterly or annual figures increasing, decreasing or remaining flat are in comparison to fiscal year 2025, and references to sequential changes are in comparison to the prior fiscal quarter. Unless stated otherwise, quarterly and annual rates and ranges are given on an organic basis.Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions, divestitures, or other significant discrete items. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.Contacts:
Justin Paquette 
Public Relations
+1-612-271-7935Ingrid Goldberg
Investor Relations
+1-763-505-2696 MEDTRONIC PLCWORLD WIDE REVENUE(1)(Unaudited)

THIRD QUARTER

YEAR-TO-DATE
REPORTED


ORGANIC

REPORTED


ORGANIC(in millions)FY26
FY25
Growth
Currency
Impact(4)
FY26(5)
FY25(5)
Growth

FY26
FY25
Growth
Currency
Impact(4)
FY26(6)
FY25(6)
GrowthCardiovascular$     3,457
$  3,037
13.8 %
$         99
$     3,359
$     3,037
10.6 %

$   10,179
$     9,145
11.3 %
$        213
$     9,966
$     9,145
9.0 %Cardiac Rhythm & Heart Failure    1,856
1,545
20.1
48
1,808
1,545
17.0

5,394
4,659
15.8
107
5,287
4,659
13.5Structural Heart & Aortic929
874
6.3
32
897
874
2.6

2,814
2,610
7.8
71
2,743
2,610
5.1Coronary & Peripheral Vascular672
618
8.8
18
654
618
5.9

1,971
1,876
5.0
35
1,935
1,876
3.1Neuroscience2,558
2,458
4.1
38
2,520
2,458
2.5

7,536
7,226
4.3
81
7,455
7,226
3.2Cranial & Spinal Technologies1,310
1,250
4.8
13
1,296
1,250
3.7

3,819
3,632
5.1
31
3,788
3,632
4.3Specialty Therapies746
732
1.9
15
731
732
(0.2)

2,191
2,181
0.4
28
2,163
2,181
(0.8)Neuromodulation503
476
5.8
10
493
476
3.6

1,527
1,413
8.1
22
1,504
1,413
6.5Medical Surgical2,173
2,072
4.9
61
2,112
2,057
2.7

6,428
6,196
3.7
128
6,295
6,164
2.1Surgical & Endoscopy1,654
1,596
3.6
51
1,603
1,581
1.4

4,945
4,790
3.2
106
4,834
4,758
1.6Acute Care & Monitoring519
476
9.1
10
509
476
7.0

1,483
1,406
5.5
22
1,461
1,406
3.9Diabetes796
694
14.8
44
751
694
8.3

2,274
2,027
12.2
90
2,184
2,027
7.8Total Reportable Segments8,985
8,260
8.8
242
8,743
8,245
6.0

26,417
24,593
7.4
512
25,901
24,562
5.4Other(2)32
32
3.0
—
—
—
—

140
17
NM(3)
4
—
—
—TOTAL$     9,017
$  8,292
8.7 %
$        243
$     8,743
$     8,245
6.0 %

$   26,557
$   24,610
7.9 %
$        516
$   25,901
$   24,562
5.4 %

See description of non-GAAP financial measures contained in the press release dated February 17, 2026.

(1)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.(2)Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, and for the year-to-date figures, adjustments to the Company's Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015.(3)Not meaningful (NM).(4)The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.(5)The three months ended January 23, 2026 excludes $275 million of revenue adjustments, including $32 million of inorganic revenue for the transition activity noted in (2) and $242 million of favorable currency impact on the remaining segments. The three months ended January 24, 2025 excludes $47 million of revenue adjustments, including $32 million of inorganic revenue related to the transition activity noted in (2) and $15 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.(6)The nine months ended January 23, 2026 excludes $656 million of revenue adjustments, including $39 million reduction in the Italian payback accruals due to changes in estimates further described in note (2), $101 million of inorganic revenue for the transition activity noted in (2), $5 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division, and $512 million of favorable currency impact on the remaining segments. The nine months ended January 24, 2025 excludes $48 million of revenue adjustments, including $90 million of incremental Italian payback accruals further described in note (2), $106 million of inorganic revenue related to the transition activity noted in (2), and $31 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division. MEDTRONIC PLCU.S. REVENUE(1)(2) (Unaudited)

THIRD QUARTER

YEAR-TO-DATE
REPORTED
ORGANIC

REPORTED
ORGANIC(in millions)FY26
FY25
Growth
FY26
FY25
Growth

FY26
FY25
Growth
FY26
FY25
GrowthCardiovascular$     1,589
$     1,405
13.1 %
$     1,589
$     1,405
13.1 %

$     4,660
$     4,242
9.9 %
$     4,660
$     4,242
9.9 %Cardiac Rhythm & Heart Failure   953
775
23.0
953
775
23.0

2,708
2,309
17.3
2,708
2,309
17.3Structural Heart & Aortic367
372
(1.4)
367
372
(1.4)

1,128
1,129
—
1,128
1,129
—Coronary & Peripheral Vascular269
258
4.2
269
258
4.2

824
804
2.5
824
804
2.5Neuroscience1,709
1,689
1.2
1,709
1,689
1.2

5,063
4,931
2.7
5,063
4,931
2.7Cranial & Spinal Technologies977
943
3.6
977
943
3.6

2,833
2,724
4.0
2,833
2,724
4.0Specialty Therapies402
419
(4.0)
402
419
(4.0)

1,204
1,235
(2.5)
1,204
1,235
(2.5)Neuromodulation330
327
1.1
330
327
1.1

1,026
972
5.6
1,026
972
5.6Medical Surgical929
893
4.1
929
893
4.1

2,756
2,718
1.4
2,756
2,718
1.4Surgical & Endoscopy634
623
1.7
634
623
1.7

1,920
1,928
(0.4)
1,920
1,928
(0.4)Acute Care & Monitoring295
269
9.5
295
269
9.5

836
790
5.8
836
790
5.8Diabetes248
236
4.9
248
236
4.9

695
683
1.7
695
683
1.7Total Reportable Segments4,475
4,223
6.0
4,475
4,223
6.0

13,174
12,573
4.8
13,174
12,573
4.8Other(3)18
15
23.4
—
—
—

60
51
16.8
—
—
—TOTAL$     4,493
$     4,237
6.0 %
$     4,475
$     4,223
6.0 %

$   13,234
$   12,624
4.8 %
$   13,174
$   12,573
4.8 %

See description of non-GAAP financial measures contained in the press release dated February 17, 2026.

(1)U.S. includes the United States and U.S. territories.(2)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.(3)Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested. MEDTRONIC PLCINTERNATIONAL REVENUE(1)(Unaudited)

THIRD QUARTER

YEAR-TO-DATE
REPORTED


ORGANIC

REPORTED


ORGANIC(in millions)FY26
FY25
Growth
Currency
Impact(4)
FY26(5)
FY25(5)
Growth

FY26
FY25
Growth
Currency
Impact(4)
FY26(6)
FY25(6)
GrowthCardiovascular$     1,868
$     1,632
14.5 %
$         99
$     1,770
$     1,632
8.5 %

$     5,519
$     4,904
12.5 %
$        213
$     5,306
$     4,904
8.2 %Cardiac Rhythm & Heart Failure   903
770
17.3
48
855
770
11.0

2,686
2,350
14.3
107
2,580
2,350
9.8Structural Heart & Aortic562
502
12.0
32
530
502
5.5

1,686
1,482
13.8
71
1,615
1,482
9.0Coronary & Peripheral Vascular403
360
12.2
18
385
360
7.1

1,146
1,072
6.9
35
1,111
1,072
3.6Neuroscience849
769
10.4
38
811
769
5.4

2,474
2,295
7.8
81
2,392
2,295
4.2Cranial & Spinal Technologies333
307
8.4
13
320
307
4.1

985
907
8.6
31
955
907
5.2Specialty Therapies343
313
9.7
15
328
313
5.0

987
947
4.3
28
959
947
1.3Neuromodulation173
149
16.0
10
163
149
9.1

501
441
13.5
22
478
441
8.4Medical Surgical1,244
1,180
5.5
61
1,183
1,165
1.6

3,671
3,478
5.6
128
3,539
3,447
2.7Surgical & Endoscopy1,020
973
4.8
51
969
958
1.1

3,024
2,862
5.7
106
2,914
2,831
2.9Acute Care & Monitoring224
206
8.5
10
214
206
3.8

647
616
5.0
22
625
616
1.4Diabetes548
457
19.8
44
504
457
10.1

1,579
1,344
17.5
90
1,489
1,344
10.9Total Reportable Segments4,510
4,038
11.7
242
4,267
4,023
6.1

13,243
12,020
10.2
512
12,726
11,989
6.2Other(2)14
17
(14.6)
—
—
—
—

80
(35)
NM(3)
4
—
—
—TOTAL$     4,524
$     4,055
11.6 %
$        243
$     4,267
$     4,023
6.1 %

$   13,323
$   11,986
11.2 %
$        516
$   12,726
$   11,989
6.2 %

See description of non-GAAP financial measures contained in the press release dated February 17, 2026.

(1)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.(2)Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested, and for the year-to-date figures, adjustments to the Company's Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015.(3)Not meaningful (NM).(4)The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.(5)The three months ended January 23, 2026 excludes $257 million of revenue adjustments, including $14 million of inorganic revenue for the transition activity noted in (2) and $242 million of favorable currency impact on the remaining segments. The three months ended January 24, 2025 excludes $32 million of revenue adjustments, including $17 million of inorganic revenue related to the transition activity noted in (2) and $15 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division.(6)The nine months ended January 23, 2026 excludes $597 million of revenue adjustments, including $39 million reduction in the Italian payback accruals due to changes in estimates further described in note (2), $41 million of inorganic revenue for the transition activity noted in (2), $5 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division, and $512 million of favorable currency impact on the remaining segments. The nine months ended January 24, 2025 excludes $3 million of revenue adjustments, including $90 million of incremental Italian payback accruals further described in note (2), $55 million of inorganic revenue related to the transition activity noted in (2), and $31 million of inorganic revenue related to a sale of business in the Surgical and Endoscopy division. MEDTRONIC PLCCONSOLIDATED STATEMENTS OF INCOME(Unaudited) 

Three months ended
Nine months ended(in millions, except per share data)January 23, 2026
January 24, 2025
January 23, 2026
January 24, 2025Net sales$              9,017
$              8,292
$           26,557
$           24,610Costs and expenses:






Cost of products sold, excluding amortization of intangible assets   3,261
2,779
9,323
8,485Research and development expense722
675
2,202
2,048Selling, general, and administrative expense2,956
2,717
8,727
8,129Amortization of intangible assets441
416
1,364
1,243Restructuring charges, net77
43
131
120Certain litigation charges, net62
22
89
104Other operating expense (income), net35
(5)
126
(38)Operating profit1,464
1,646
4,594
4,519Other non-operating income, net(121)
(72)
(247)
(403)Interest expense, net181
179
539
555Income before income taxes1,404
1,540
4,302
4,367Income tax provision254
237
724
737Net income1,150
1,303
3,578
3,630Net income attributable to noncontrolling interests(6)
(9)
(21)
(24)Net income attributable to Medtronic$              1,143
$              1,294
$             3,557
$             3,606Basic earnings per share$                0.89
$                1.01
$               2.77
$               2.80Diluted earnings per share$                0.89
$                1.01
$               2.76
$               2.79Basic weighted average shares outstanding1,282.6
1,282.4
1,282.1
1,286.7Diluted weighted average shares outstanding1,289.5
1,286.2
1,288.2
1,290.6
The data in the schedule above has been intentionally rounded to the nearest million. MEDTRONIC PLCGAAP TO NON-GAAP RECONCILIATIONS(1)(Unaudited) 


Three months ended January 23, 2026(in millions, except per share data)Net
Sales
Cost of
Products
Sold
Gross
Margin
Percent
Operating
Profit
Operating
Profit
Percent
Income
Before
Income
Taxes
Net Income
attributable
to
Medtronic
Diluted
EPS
Effective
Tax RateGAAP$  9,017
$   3,261
63.8 %
$     1,464
16.2 %
$    1,404
$       1,143
$     0.89
18.1 %Non-GAAP Adjustments:
















Amortization of intangible assets(2)—
—
—
441
4.9
441
360
0.28
18.4Restructuring and associated costs(3)—
(89)
1.0
172
1.9
172
141
0.11
18.0Acquisition and divestiture-related items(4)—
(6)
0.1
38
0.4
38
33
0.03
13.2Certain litigation charges, net—
—
—
62
0.7
62
52
0.04
16.1(Gain)/loss on minority investments(5)—
—
—
—
—
8
7
0.01
12.5Certain tax adjustments, net—
—
—
—
—
—
14
0.01
—Non-GAAP$  9,017
$   3,166
64.9 %
$     2,177
24.1 %
$    2,125
$       1,750
$     1.36
17.3 %Currency impact(243)
(52)
(0.4)
(67)
(0.1)




(0.04)

Currency Adjusted$  8,775
$   3,114
64.5 %
$     2,110
24.0 %




$     1.32




















Three months ended January 24, 2025(in millions, except per share data)Net
Sales
Cost of
Products
Sold
Gross
Margin
Percent
Operating
Profit
Operating
Profit
Percent
Income
Before
Income
Taxes
Net Income
attributable
to
Medtronic
Diluted
EPS
Effective
Tax RateGAAP$  8,292
$   2,779
66.5 %
$     1,646
19.9 %
$    1,540
$       1,294
$     1.01
15.4 %Non-GAAP Adjustments:
















Amortization of intangible assets—
—
—
416
5.0
416
339
0.26
18.5Restructuring and associated costs(3)—
(4)
—
46
0.6
46
37
0.03
19.6Acquisition and divestiture-related items(4)   —
(1)
—
28
0.3
28
23
0.02
17.9Certain litigation charges, net—
—
—
22
0.3
22
18
0.01
22.7(Gain)/loss on minority investments(5)—
—
—
—
—
68
52
0.04
22.1Medical device regulations(6)—
(8)
0.1
11
0.1
11
9
0.01
18.2Certain tax adjustments, net—
—
—
—
—
—
15
0.01
—Non-GAAP$  8,292
$   2,766
66.6 %
$     2,169
26.2 %
$    2,130
$       1,787
$     1.39
15.7 %

See description of non-GAAP financial measures contained in the press release dated February 17, 2026.

(1)The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.(2)The Company recognized $30 million of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio.(3)The charges primarily relate to employee termination benefits, facility related and contract termination costs, and asset write offs.(4)The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. Exit of business-related charges primarily relate to the impending separation of the Diabetes business. For the three months ended January 23, 2026, charges also include costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System.  (5)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.(6)The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs. MEDTRONIC PLCGAAP TO NON-GAAP RECONCILIATIONS(1)(Unaudited)

Nine months ended January 23, 2026(in millions, except per share data)Net
Sales
Cost of
Products
Sold
Gross
Margin
Percent
Operating
Profit
Operating
Profit
Percent
Income
Before
Income
Taxes
Net Income
attributable
to Medtronic
Diluted
EPS
Effective
Tax RateGAAP$ 26,557
$   9,323
64.9 %
$     4,594
17.3 %
$    4,302
$         3,557
$     2.76
16.8 %Non-GAAP Adjustments:
















Amortization of intangible assets(2)—
—
—
1,364
5.2
1,364
1,110
0.86
18.6Restructuring and associated costs(3)—
(105)
0.4
251
1.0
251
202
0.16
19.5Acquisition and divestiture-related items(4)—
(21)
—
96
0.4
96
73
0.06
24.0Certain litigation charges, net—
—
—
89
0.3
89
73
0.06
19.1(Gain)/loss on minority investments(5)—
—
—
—
—
145
137
0.11
5.5Other(6)(39)
—
—
(39)
(0.1)
(39)
(30)
(0.02)
20.5Certain tax adjustments, net(7)—
—
—
—
—
—
—
—
—Non-GAAP$ 26,518
$   9,197
65.3 %
$     6,356
24.0 %
$    6,209
$         5,122
$     3.98
17.2 %Currency impact(513)
(48)
(0.5)
(170)
(0.2)




(0.10)

Currency Adjusted$ 26,005
$   9,149
64.8 %
$     6,185
23.8 %




$     3.88




















Nine months ended January 24, 2025(in millions, except per share data)Net
Sales
Cost of
Products
Sold
Gross
Margin
Percent
Operating
Profit
Operating
Profit
Percent
Income
Before
Income
Taxes
Net Income
attributable
to Medtronic
Diluted
EPS
Effective
Tax RateGAAP$ 24,610
$   8,485
65.5 %
$     4,519
18.4 %
$    4,367
$         3,606
$     2.79
16.9 %Non-GAAP Adjustments:
















Amortization of intangible assets—
—
—
1,243
4.9
1,243
1,017
0.79
18.3Restructuring and associated costs(3)—
(24)
0.1
154
0.6
154
124
0.10
19.5Acquisition and divestiture-related items(4)   —
(17)
—
15
0.1
15
3
—
73.3Certain litigation charges, net—
—
—
104
0.4
104
86
0.07
17.3(Gain)/loss on minority investments(5)—
—
—
—
—
41
14
0.01
61.0Medical device regulations(8)—
(27)
0.1
38
0.2
38
30
0.02
21.1Other(6)90
—
0.2
90
0.4
90
70
0.05
22.2Certain tax adjustments, net(7)—
—
—
—
—
—
49
0.04
—Non-GAAP$ 24,700
$   8,417
65.9 %
$     6,162
24.9 %
$    6,051
$         4,999
$     3.87
17.0 %

See description of non-GAAP financial measures contained in the press release dated February 17, 2026.

(1)The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.(2)The Company recognized $121 million of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio.(3)The charges primarily relate to employee termination benefits, facility related and contract termination costs, and asset write offs.(4)The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. Exit of business-related charges primarily relate to the impending separation of the Diabetes business and costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System.(5)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. (6)Reflects adjustments to the Company's Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015.(7)The charges for the nine months ended January 23, 2026 primarily includes a tax benefit recognized due to a change in interest accrued on uncertain tax positions, offset by amortization of previously established deferred tax assets arising from intercompany intellectual property transactions. The charges for the nine months ended January 24, 2025 primarily includes amortization of previously established deferred tax assets arising from intercompany intellectual property transactions.(8)The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs. MEDTRONIC PLCGAAP TO NON-GAAP RECONCILIATIONS(1)(Unaudited) 

Three months ended January 23, 2026(in millions)Net Sales
SG&A
Expense
SG&A
Expense as
a % of Net
Sales
R&D
Expense
R&D
Expense
as a % of
Net Sales
Other
Operating
(Income)
Expense,
net
Other
Operating
(Inc.)/Exp.,
net as a % of
Net Sales
Other Non-
Operating
Income, netGAAP$      9,017
$     2,956
32.8 %
$       722
8.0 %
$           35
0.4 %
$          (121)Non-GAAP Adjustments:














Restructuring and associated costs(2)—
(6)
(0.1)
—
—
—
—
—Acquisition and divestiture-related items(3)   —
(35)
(0.4)
—
—
3
—
—(Gain)/loss on minority investments(4)—
—
—
—
—
—
—
(8)Non-GAAP$      9,017
$     2,914
32.3 %
$       722
8.0 %
$           38
0.4 %
$          (130)
















Nine months ended January 23, 2026(in millions)Net Sales
SG&A
Expense
SG&A
Expense as
a % of Net
Sales
R&D
Expense
R&D
Expense
as a % of
Net Sales
Other
Operating
(Income)
Expense,
net
Other
Operating
(Inc.)/Exp.,
net as a % of
Net Sales
Other Non-
Operating
Income, netGAAP$    26,557
$     8,727
32.9 %
$    2,202
8.3 %
$         126
0.5 %
$          (247)Non-GAAP Adjustments:














Restructuring and associated costs(2)—
(15)
—
—
—
—
—
—Acquisition and divestiture-related items(3)   —
(96)
(0.3)
—
—
21
0.1
—Other(5)(39)
—
—
—
—
—
—
—(Gain)/loss on minority investments(4)—
—
—
—
—
—
—
(145)Non-GAAP$    26,518
$     8,616
32.5 %
$    2,202
8.3 %
$         147
0.6 %
$          (392)

See description of non-GAAP financial measures contained in the press release dated February 17, 2026.

(1)The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.(2)The charges primarily relate to employee termination benefits, facility related and contract termination costs, and asset write offs.(3)The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. Exit of business-related charges primarily relate to the impending separation of the Diabetes business and costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System.(4)We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.(5)Reflects adjustments to the Company's Italian payback accruals resulting from the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015. MEDTRONIC PLCGAAP TO NON-GAAP RECONCILIATIONS(1)(Unaudited)

Nine months ended(in millions)January 23, 2026
January 24, 2025Net cash provided by operating activities$                      4,757
$                      4,516Additions to property, plant, and equipment   (1,416)
(1,400)Free Cash Flow(2)$                      3,341
$                      3,116

See description of non-GAAP financial measures contained in the press release dated February 17, 2026.

(1)The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.(2)Free cash flow represents operating cash flows less property, plant, and equipment additions. MEDTRONIC PLCCONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)

Nine months ended(in millions)January 23, 2026
January 24, 2025Operating Activities:


Net income$                3,578
$                3,630Adjustments to reconcile net income to net cash provided by operating activities:   


Depreciation and amortization2,242
2,021Provision for credit losses102
96Deferred income taxes59
(81)Stock-based compensation362
340Other, net280
14Change in operating assets and liabilities, net of acquisitions and divestitures:


Accounts receivable, net87
(184)Inventories(803)
(478)Accounts payable and accrued liabilities(77)
(157)Other operating assets and liabilities(1,074)
(685)Net cash provided by operating activities4,757
4,516Investing Activities:


Acquisitions, net of cash acquired—
(98)Additions to property, plant, and equipment(1,416)
(1,400)Purchases of investments(6,572)
(6,093)Sales and maturities of investments5,982
6,255Other investing activities, net(10)
(111)Net cash used in investing activities(2,017)
(1,447)Financing Activities:


Change in current debt obligations, net173
(1,070)Issuance of long-term debt1,747
3,209Payments on long-term debt(2,930)
—Dividends to shareholders(2,731)
(2,692)Issuance of ordinary shares419
400Repurchase of ordinary shares(600)
(2,961)Other financing activities, net60
96Net cash used in financing activities(3,863)
(3,018)Effect of exchange rate changes on cash and cash equivalents52
(95)Net change in cash and cash equivalents(1,072)
(44)Cash and cash equivalents at beginning of period2,218
1,284Cash and cash equivalents at end of period$                1,147
$                1,240



Supplemental Cash Flow Information


Cash paid for:


Income taxes$                1,598
$                1,515Interest573
567
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. 



















View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-reports-strong-third-quarter-fiscal-2026-results-with-highest-enterprise-revenue-growth-in-10-quarters-302689151.htmlSOURCE Medtronic plc

Original: Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters

Medtronic receives FDA clearance for Stealth AXiS™ surgical system, first integrated planning, navigation and robotics platform for spine surgeryFebruary 13, 2026 8:00 AM
PR Newswire (US)

GALWAY, Ireland, Feb. 13, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system, a next-generation platform that brings planning, navigation, and robotics together into a single, intelligent system for spine surgery.







The Stealth AXiS™ system is cleared for spine procedures in the United States, with an underlying architecture designed to support future cranial and ENT applications, pending 510(k) clearance. Built to support a wide range of surgeon preferences, clinical complexity, and care settings, the platform is designed for use across hospitals and ambulatory surgery centers without relying on multiple standalone technologies.Grounded in more than 50 years of Medtronic leadership in surgical navigation and robotics, the Stealth AXiS™ system creates a clear pathway for adoption by combining familiar navigation workflows with a modular robotic design, allowing institutions to deploy what they need today and expand over time as clinical needs evolve."The Stealth AXiS™ system represents a meaningful step forward in how we think about navigation and robotics working together," said Ronald A. Lehman, Jr., M.D., Tenured Professor of Orthopaedic Surgery (Neurological Surgery) at Columbia University, Division Chief of Spine Surgery, and Spine Medical Director at The Spine Hospital at NewYork-Presbyterian/The Allen Hospital, and a paid consultant to Medtronic. "One of the biggest challenges in spine surgery has been understanding and responding to how the spine moves during a procedure. The Stealth AXiS™ system gives surgeons real-time visibility into that motion, helping us more consistently achieve our surgical plan without interrupting workflow. To me, this is truly game changing technology."A key innovation of the Stealth AXiS™ system is LiveAlign™ segmental tracking, an industry-first capability that allows surgeons to visualize anatomic motion, surgical adjustments, and patient alignment in real time during spine surgery, without the need for repeated imaging. This capability helps reduce reliance on manual steps and workflow disruption, supporting more consistent execution of patient-specific surgical plans.As a cornerstone of Medtronic's AiBLE™ smart ecosystem, the Stealth AXiS™ system enables a more intuitive and seamless flow of information across the surgical continuum. By natively integrating planning, navigation, and execution within a single platform, the Stealth AXiS™ system helps streamline workflows and supports the exchange of insights before, during, and after spine surgery, allowing the broader AiBLE™ ecosystem to connect devices, software, and data in a more meaningful way."Spine surgery is complex, and variability remains a real challenge," said Michael Carter, Senior Vice President and President of Medtronic Cranial & Spinal Technologies. "The Stealth AXiS™ system is designed to make advanced technology more usable and clinically meaningful, helping surgeons deliver more predictable, personalized care while laying the foundation for continued innovation."The Stealth AXiS™ surgical system reflects Medtronic's focus on building durable platforms that simplify surgical workflows today while enabling future expansion across procedures, specialties, and care settings.For more information about the Stealth AXiS™ surgical system and the AiBLE™ smart ecosystem, visit www.Medtronic.com/StealthAxis.About the Cranial & Spinal Technologies Business at Medtronic
As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, we serve over 4 million patients annually. Building on a legacy of innovation, our AiBLE™ ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and achieve better outcomes, before, during, and beyond surgery.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Contacts:
Christine Stewart
Public Relations
+1-269-377-2557Ingrid Goldberg
Investor Relations
+1-763-505-2696










View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-receives-fda-clearance-for-stealth-axis-surgical-system-first-integrated-planning-navigation-and-robotics-platform-for-spine-surgery-302687132.htmlSOURCE Medtronic plc

Original: Medtronic receives FDA clearance for Stealth AXiS™ surgical system, first integrated planning, navigation and robotics platform for spine surgery

Medtronic to announce financial results for its third quarter of fiscal year 2026February 11, 2026 1:56 PM
PR Newswire (US)

GALWAY, Ireland, Feb. 11, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, February 17, 2026, for its third quarter of fiscal year 2026, which ended on Friday, January 23, 2026.A news release containing summary financial information will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://news.medtronic.comA video webcast to discuss results will begin at 7:00 a.m. CST and can be accessed at https://investorrelations.medtronic.comWithin 24 hours of the video webcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at https://investorrelations.medtronic.com.About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Contacts:
Justin Paquette
Public Relations
+1-612-271-7935Ingrid Goldberg 
Investor Relations 
+1-763-505-2696 





View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-to-announce-financial-results-for-its-third-quarter-of-fiscal-year-2026-302685523.htmlSOURCE Medtronic plc

Original: Medtronic to announce financial results for its third quarter of fiscal year 2026

Medtronic advances its innovation strategy with intent to acquire CathWorksFebruary 3, 2026 8:17 AM
PR Newswire (US)

Deal demonstrates Medtronic's commitment to expanding pipeline through strategic investments and targeted acquisitions Exercising option to acquire will bolster Medtronic's interventional cardiology portfolio, expanding its leadership in transforming how cardiovascular disease is diagnosed and treatedMedtronic's intent to acquire follows a 2022 strategic partnership agreement with CathWorks GALWAY, Ireland, Feb. 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will exercise its option to acquire CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System in the U.S., Europe and Japan, where it is commercially available. The acquisition is valued at up to $585 million with potential undisclosed earn-out payments post-acquisition."Medtronic is thrilled to move forward with our option to officially acquire CathWorks. Through our co-promotion agreement, we've seen how CathWorks can disrupt the traditional wire-based FFR segment and leverage the power of data and AI to deliver innovative solutions that assist physicians at every step of a patient's journey, from diagnosis to treatment," said Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business, which is part of the Cardiovascular Portfolio at Medtronic. "This acquisition allows Medtronic to transform the cath lab with a technology that provides real-time data, informs individualized treatment approaches, and drives new standards of care." Evaluating the physiological significance of coronary artery stenosis is essential to improving patient outcomes. Coronary physiology, most commonly assessed using fractional flow reserve (FFR), helps physicians identify which lesions truly cause ischemia. This enables appropriate revascularization for patients who need it, while avoiding unnecessary percutaneous coronary intervention (PCI) in those who do not. FFR is an important diagnostic tool with strong clinical evidence that demonstrates its improved clinical outcomes and economic benefits.1, 2 Despite its proven benefits, traditional wire-based FFR remains underutilized. This is largely due to its invasive nature, which requires the use of pressure wires, pharmacologic hyperemia, and measurements limited to a single transducer location within the vessel.Alternatively, using a combination of artificial intelligence (AI) and advanced computational science, the CathWorks FFRangio System provides a comprehensive physiological assessment of the entire coronary tree directly from routine coronary angiograms (X-rays). Robust clinical evidence has demonstrated excellent diagnostic accuracy and promising clinical outcomes when compared with wire-based FFR.3,4  "We are thrilled to have CathWorks officially become part of the Medtronic family," said Ramin Mousavi, president and chief executive officer of CathWorks. "Our successful co-promotion over the past three years has unlocked significant opportunities in the coronary physiology market through the expanded utilization of our innovative technology. With Medtronic's vast global footprint, FFRangio will continue to reach even more patients globally. Bringing Medtronic and CathWorks together will create a best-in-class organization focused on driving new standards of care to transform the cath lab."  This deal is pending clearance from the United States Federal Trade Commission (FTC). This phase is expected to be completed by the end of Medtronic's fiscal year 2026, subject to applicable regulatory approvals and other customary closing conditions. At the date of the acquisition closing, CathWorks will then become a part of Medtronic. Medtronic and CathWorks will continue to operate independently until the deal is closed.Financial Highlights
This acquisition is expected to be immaterial to Medtronic's fiscal year 2027 GAAP and adjusted earnings per share and neutral to accretive thereafter.About FFRangio
Using a combination of artificial intelligence (AI) and advanced computational science, the CathWorks FFRangio® System is the only angiography-derived system that delivers FFR values along the entire coronary tree. In addition, it provides intraprocedural optimization tools, including assessment of the physiological impact of lesion treatment and interactive sizing tools to measure lesion dimensions. Together, these capabilities empower physicians with deeper physiological insights to support confident, patient-centered treatment decisions.*About CathWorks
CathWorks, based in Kfar Saba, Israel, is the leader in coronary digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFR values for the entire coronary tree. For more information on CathWorks, visit www.cath.works and follow @CathWorks on Twitter and LinkedIn. About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.*The results of CathWorks FFRangio®  are intended to be used by qualified clinicians in conjunction with the patient's clinical history, symptoms, and other diagnostic tests, as well as the clinician's professional evaluation.1. Bernard De Bruyne, M.D., Ph.D., Nico H.J. Pijls, M.D., Ph.D., Bindu Kalesan, M.P.H., Emanuele Barbato, M.D., Ph.D., Pim A.L. Tonino, M.D., Ph.D., Zsolt Piroth, M.D., Nikola Jagic, M.D., Sven Möbius-Winkler, M.D., Gilles Rioufol, M.D., Ph.D., Nils Witt, M.D., Ph.D., Petr Kala, M.D., Philip MacCarthy, M.D., Thomas Engström, M.D., Keith G. Oldroyd, M.D., Kreton Mavromatis, M.D., Ganesh Manoharan, M.D., Peter Verlee, M.D., Ole Frobert, M.D., Nick Curzen, B.M., Ph.D., Jane B. Johnson, R.N., B.S.N., Peter Jüni, M.D., and William F. Fearon, M.D., for the FAME 2 Trial Investigators. Fractional Flow Reserve–Guided PCI versus Medical Therapy in stable coronary disease. The New England Journal of Medicine 2012; 367:991-1001DOI: 10.1056/NEJMoa12053612. Fearon et al. Economic Evaluation of Fractional Flow Reserve-guided Percutaneous Coronary Intervention in Patients with Multivessel Disease. Circulation. 2010;122:2545-2550.3. Witberg G, De Bruyne B, Fearon WF, Achenbach S, Engstrom T, Matsuo H, et al. Diagnostic performance of angiogram-derived fractional flow reserve: a pooled analysis of 5 prospective cohort studies. JACC Cardiovasc Interv. (2020) 13:488–97. 10.1016/j.jcin.2019.10.0454. Tanigaki T, et al. Provision Trial. Data presented at PCR 2025; Paris, FranceContacts:
Krystin Hayward
Public Relations
+1-508-261-6512Ingrid Goldberg
Investor Relations
 +1-763-505-2696 





View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-advances-its-innovation-strategy-with-intent-to-acquire-cathworks-302677648.htmlSOURCE Medtronic plc

Original: Medtronic advances its innovation strategy with intent to acquire CathWorks

Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearancesFebruary 2, 2026 9:17 AM
PR Newswire (US)

GALWAY, Ireland, Feb. 2, 2026  /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that expand access, choice, and flexibility for people living with type 1 and insulin-requiring type 2 diabetes. These milestones include Medicare access for the MiniMed™ 780G system paired with the Instinct sensor, made by Abbott, FDA clearance for the system's use with ultra rapid-acting insulins, and clearance of the MiniMed™ 780G system for use with the Instinct sensor for insulin-requiring type 2 diabetes.







"These milestones reflect our unwavering commitment to expanding access and giving individuals living with diabetes more choice in how they manage their condition," said Que Dallara, EVP & president, Medtronic Diabetes. "By broadening sensor and insulin options for the MiniMed™ 780G system, we're empowering more people to benefit from automated insulin delivery that supports easier mealtimes, greater flexibility, and more confident diabetes management—making everyday life a bit easier."Medicare Access for MiniMed™ 780G System with Instinct Sensor, Made by Abbott
Medicare and Medicare Advantage beneficiaries can now access the MiniMed™ 780G system with the Instinct sensor, made by Abbott. The Instinct sensor is small, thin, and worn discreetly, with up to 15 days of wear. This milestone expands sensor choice for Medicare users, who also have access to the Simplera Sync™ and Guardian™ 4 sensors.Access to advanced technologies like the MiniMed™ 780G system can help reduce burden by automating insulin delivery, responding to glucose changes every five minutes, and supporting more stable glucose control. This means fewer highs and lows, less daily decision-making, and a more streamlined way to stay within recommended glucose ranges.§Medicare customers who previously placed orders for the MiniMed™ 780G system with the Instinct sensor will now advance through the standard Medicare billing and fulfillment process, subject to individual eligibility and insurance requirements.  Medtronic Diabetes is also working closely with distributor partners to support readiness and timely shipment for eligible customers.Ultra Rapid-Acting Insulins for MiniMed™ 780G System
The FDA cleared the MiniMed™ 780G system for use with ultra rapid-acting insulins Fiasp and Lyumjev, giving people living with type 1 and insulin-requiring type 2 diabetes more flexibility and personalization in their therapy.Ultra rapid-acting insulin more closely mimics the body's natural insulin response, especially around mealtimes. Its faster onset may help reduce the impact of late or missed meal doses, allowing the insulin to "catch up" more effectively.1 When paired with the MiniMed™ 780G system's unique Meal Detection™ technology, these insulin options can help take the burden and pressure off mealtimes when carb counts aren't exact or a meal dose is sometimes missed or delayed. This new clearance allows clinicians and individuals to choose the insulin that best matches their physiology and lifestyle, supporting more customized therapy and potentially improving overall glucose outcomes.MiniMed™ 780G System for use with Instinct Sensor FDA Cleared for Type 2 Diabetes
The FDA cleared the SmartGuard™ algorithm as an interoperable automated glycemic controller (iAGC) and the MiniMed™ 780G insulin pump as an alternate controller enabled (ACE) for insulin-requiring type 2 diabetes, enabling integration with the Instinct sensor, made by Abbott.People living with insulin-requiring type 2 diabetes navigate a demanding daily routine that impacts both their physical and emotional well-being—from multiple injections to constant meal planning and vigilant glucose monitoring. The MiniMed™ 780G system can help lighten the daily load by automatically adjusting insulin delivery every five minutes and stepping in to help manage missed or underestimated meal boluses. Paired with the Instinct sensor, users will soon have access to the company's most advanced automated insulin delivery system with the world's smallest and thinnest integrated sensor that offers up to 15 days of wear, is slim and worn discreetly.2,3"Bringing together the Instinct sensor, made by Abbott, with the well-established algorithm of the MiniMed™ 780G system makes for an extremely effective combination," said Anders Carlson, MD, Associate Executive Director, International Diabetes Center in Minneapolis, Minnesota. "I think anyone who requires insulin therapy to manage their diabetes, whether it's type 1 or type 2 diabetes, can benefit from automated insulin delivery. I'm thrilled that the MiniMed™ 780G system with the Instinct sensor is now cleared for this population, so that more people living with type 2 diabetes will get access to this life-changing technology improving their day-to-day experience in managing their diabetes."The MiniMed™ 780G system for insulin-requiring type 2 diabetes is now can now be ordered with Instinct along with the Guardian™ 4 and Simplera Sync™ sensors. The Instinct sensor, made by Abbott, is currently available for type 1 diabetes. Learn more about the MiniMed™ 780G system here. Frequently Asked Questions Q: What is the MiniMed™ 780G system?
A: It's Medtronic's most advanced automated insulin delivery system that automatically adjusts insulin every five minutes based on real-time glucose readings, helping reduce highs and lows and making diabetes management easier and less time-consuming.§Q: What makes the Instinct sensor different?
A: The Instinct sensor, made by Abbott, offers up to 15 days of wear, is slim and worm discreetly. It's the world's smallest and thinnest integrated CGM.2,3Q: What is ultra rapid-acting insulin and the benefit for AID systems?
Ultra rapid-acting insulins enter the bloodstream and start working sooner than traditional rapid-acting insulins, helping manage post-meal spikes—especially when individuals can't or forget to pre-bolus 15 minutes before eating.4About the Diabetes Business at Medtronic
Medtronic Diabetes is on a mission to make diabetes more predictable with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront. About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.Rakab MS, Rateb RM, Elsalakawi BH, Al Zoubi BM, Nazir A, Abu-Laila MM, Ghanem AS, Maamoun A, Mattar M, Ataallah B, Layden BT, Mahmoud AM. Ultra-rapid lispro or fast-acting aspart compared to standard insulin lispro and aspart using closed-loop insulin therapy: a systematic review and meta-analysis of randomized control trials. Front Endocrinol (Lausanne). 2025 Jun 6;16:1600157.Among applied sensors.Data on file. Abbott Diabetes Care, Inc.Eva Y. Wong, Lisa Kroon; Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?. Clin Diabetes 1 October 2021; 39 (4): 415–423. https://doi.org/10.2337/cd20-0119§ Refers to SmartGuard™ feature. Individual results may varyThe sensor shape and appearance, Abbott, and Instinct are marks and/or designs of the Abbott group of companies in various territories and used under license.Fiasp is a registered trademark of Novo Nordisk A/S and Lyumjev is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.Contacts:
Janet Cho
Global Communications
+1 (818) 403-7028Ryan Weispfenning
Investor Relations
+1 (763) 505-4626 










View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-diabetes-expands-access-to-full-stack-insulin-delivery-solutions-with-medicare-access-and-new-fda-clearances-302676383.htmlSOURCE Medtronic plc

Original: Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances

I understand the Florida division is starting to turn back on. They are important to the qtr.

1 ~ FAKSOVA ET AL: (n=99 million participants)

“COVID-19 Vaccines & adverse events of special interest: A Multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals”

:KEY POINTS:

~Myocarditis rate: (+510% increase after mRNA shot)… pic.twitter.com/Z9KmAF258R— Lyndsey, RN 💜🐭 (@HouseLyndseyRN) May 14, 2025 $MDT

MDT at a 52 week high, 10Q due 2/18

Why the GAP up today?

This? - https://www.fiercebiotech.com/medtech/jpm25-medtronic-begins-rolling-out-adaptive-brain-stimulation-parkinsons-after-eu-approval

MDT 10Q due AUGUST 20

90 Calls for December and loading $ICCM device company that kills cancerous tumors with non invasive Freezing cryoblast platform killing a wide array of cancers approved in 15 countries.

$MDT

Adding soon at $72. Well advised to let the middle east tensions way out and the coming recession!

YES MY FRIEND

MDT
Medtronic PLC
84.11
0.00 (0.00%)
Volume: 4,187,311
Day Range: 83.54 - 84.18
Last Trade Time: 5:22:10 PM EDT

yes, they have ai stuff

RU bullish on mdt?

MDT
Medtronic PLC
84.56
-1.34 (-1.56%)
Volume: 6,358,783
Day Range: 84.48 - 85.87
Last Trade Time: 3:40:22 PM EST

no they dont,they did an add on for hugo for a sp robot wake up bro.tmdi is done with.they couldnt get the robot to market after 12 yrs,2 rs and almost 300 mill spent.mdt and isrg got what they wanted for chump change.also sp accounts for only 3 % of surgerys.God bless all and good luck 2

TMDI’s buddy

Looking at MDT here from technical standpoint ... I told myself months ago that when it got below $100, I was going to start buying MDT. Now it's there, having touched a daily low of $99.21 today 5/9/22. Plenty of technical support in this $98-99 area looking at bounces back on 12/20/21, 10/26/20, and 8/17/20. Yet the current headwinds from ramped-up inflation and long-awaited Fed tightening may hold the upper hand at this point. Surprised at the lack of posts on MDT on this board. I might test the waters tomorrow, but only to start a partial position. Anybody listening?

Medtronic - Rocket to Luna !!

It’s alive !!

Elevator going up…….all aboard ?

$$ MDT $$!

Wow, is this board dead or what??!!

Can MDT reach $150+ if we could get the 7 day Extended approved in the U.S.?

IN ORDER FOR MEDTRONIC TO BEAT INTUITIVE SURGICAL THEY NEED TO BUYOUT TITAN MEDICAL!

Medtronic's only answer to Intuitive Surgical is Titan Medical Inc. Titan holds a lot of patents that would put Medtronic as a super power medical robotic company.

YOU THINK MEDTRONIC WILL BUYOUT TITAN MEDICAL TO COMPETE AGAINST INTUITIVE SURGICAL? , I THINK THAT WOULD QUADRUPLE THE SHARE PRICE OF MEDTRONIC.

NEWS: $MDT Forget Snowflake! Buy This Ultra-High-Growth Stock

Investors have understandably bid up shares of companies that deliver software as a service this year as those companies continue to benefit from a work-from-home world. For an example, we need only to look at the initial public offering of cloud-based data and analytics company Snowflake...

Read the whole news MDT - Forget Snowflake! Buy This Ultra-High-Growth Stock

Buy buy buy

JUST IN: $MDT Nine-Month Results from Medtronic IN.PACT BTK Study Presented in Late-Breaking Clinical Trial Sessions at TCT Connect Annual Meeting

Nine-Month Results from Medtronic IN.PACT BTK Study Presented in Late-Breaking Clinical Trial Sessions at TCT Connect Annual Meeting Canada NewsWire DUBLIN, Oct. 18, 2020 Feasibility Study of Medtronic Drug-Coated Balloon Technology for Challenging Below-the-Knee D...

Read the whole news MDT - Nine-Month Results from Medtronic IN.PACT BTK Study Presented in Late-Breaking Clinical Trial Sessions at TCT Connect Annual Meeting

Let’s go....

I think it’s just big money rebalancing for the end of the quarter, I see it taking off soon

Find it hard to believe that this dipped in the last few days and again today with the news of the subpoena from an event that happened about 7 years ago and before MDT owned the then company that they purchased in 2015. Like they could have foreseen this Pandemic coming on in 2015. This shall pass and should see the $120 range.